Pharmaceutical composition comprising a triple-active compound having activity at all of glucagon, GLP-1 and GIP receptors, and insulin

A combination of insulin and a triple activator targeting glucagon, GLP-1, and GIP receptors addresses the weight gain issue of insulin treatment, enhancing blood sugar control and treating diabetes and obesity effectively.

JP7596268B2Active Publication Date: 2024-12-09HANMI PHARM CO LTD
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
JP2021536280
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2019-12-23
Publication Date
2024-12-09
Estimated Expiration
2039-12-23

AI Technical Summary

Technical Problem

Current insulin treatments for diabetic patients, particularly those with Type 1 and Type 2 diabetes, are effective in regulating blood sugar but often lead to weight gain as a side effect, and there is a need for a therapeutic agent that can reduce this side effect while maintaining blood sugar control.

Method used

A composition containing insulin and a triple activator with activity on glucagon, GLP-1, and GIP receptors, which includes a long-acting conjugate of insulin and a long-acting conjugate of the triple activator, to enhance blood sugar control and reduce weight gain.

Benefits of technology

The composition improves blood sugar control and reduces weight gain in diabetic patients by combining insulin with a triple activator, providing a therapeutic effect on insulin-related diseases like diabetes and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596268000014
    Figure 0007596268000014
  • Figure 0007596268000015
    Figure 0007596268000015
  • Figure 0007596268000001
    Figure 0007596268000001
Patent Text Reader

Abstract

The present invention relates to a composition comprising a triple-active compound having activity on all of glucagon receptors, GLP-1 receptors and GIP receptors, and insulin, as well as a combined preparation comprising the same.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition comprising a triple-active substance having activity at all of glucagon receptors, GLP-1 receptors and GIP receptors, and insulin, and a combination preparation comprising the same. [Background technology]

[0002] Insulin is a blood sugar regulating hormone secreted by the pancreas in the human body, and serves to transport excess glucose in the blood to cells, supplying them with an energy source and maintaining blood sugar at a normal level. However, in diabetic patients, insulin does not function normally due to such a lack of insulin, insulin resistance and loss of β-cell function. Therefore, diabetic patients cannot use glucose in the blood as an energy source, and develop hyperglycemic symptoms in which blood glucose levels are high, and ultimately excrete sugar in urine, which can lead to various complications. Therefore, insulin treatment is essential for diabetic patients with abnormal insulin secretion (Type I) and diabetic patients with insulin resistance (Type II), and administration of insulin can regulate blood sugar to a normal level.

[0003] Currently, 25% of type 1 diabetes and more than 80% of type 2 diabetes are not only hyperglycemic but also obese, and although administration of insulin alone is excellent for regulating blood sugar, it is known to have a side effect of weight gain. Therefore, there is a demand for the development of a therapeutic agent that can effectively reduce the side effect of weight gain while exerting the blood sugar lowering effect of insulin.

[0004] On the other hand, the present applicant has developed various insulin analogs having insulin activity (Patent Documents 1 and 2), and also developed a triple-active substance having activity on all of the glucagon receptor, the GLP-1 receptor, and the GIP receptor (Patent Documents 3 and 4). However, these have not been used as a combined preparation. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2014 / 133324 [Patent Document 2] International Publication No. 2017 / 039267 [Patent Document 3] International Publication No. 2017 / 116204 [Patent Document 4] International Publication No. 2017 / 116205 [Patent Document 5] Korean Patent Publication No. 10-2014-0106452 [Patent Document 6] Korean Patent Publication No. 10-2017-0026284 [Patent Document 7] International Publication No. 97 / 034631 [Patent Document 8] International Publication No. 96 / 032478 [Non-patent literature]

[0006] [Non-Patent Document 1] H. Neurath, RL Hill, The Proteins, Academic Press, New York, 1979 Summary of the Invention [Problem to be solved by the invention]

[0007] The present application confirmed that the combined use of insulin and the triple activity compound significantly improved blood sugar regulation ability compared to the groups administered either alone, and also effectively improved weight gain caused by insulin. [Means for solving the problem]

[0008] The present invention aims to provide a composition comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 (Glucagon-like peptide-1) receptor, and the GIP (Glucose-dependent insulinotropic polypeptide) receptor.

[0009] Specifically, the present invention aims to provide a pharmaceutical composition for preventing or treating insulin-related diseases, comprising (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0010] Another object of the present invention is to provide a pharmaceutical composition for reducing weight gain due to insulin administration, comprising (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0011] Further, the present invention aims to provide a combination formulation for weight loss in patients receiving insulin, comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0012] It is a further object of the present invention to provide a kit comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0013] A further object of the present invention is to provide a use of the composition in the manufacture of a medicament.

[0014] Furthermore, the present invention aims to provide a method for preventing or treating insulin-related diseases, comprising the steps of administering to an individual (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0015] It is a further object of the present invention to provide a method for reducing weight gain due to insulin administration comprising administering to an individual an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0016] Specifically, a method is provided for reducing weight gain due to insulin administration, comprising administering to an individual (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor. Effect of the Invention

[0017] The composition or composite preparation comprising the insulin or its long-acting conjugate of the present invention and the triple activity form or its long-acting conjugate provides a novel combination therapy that exerts preventive or therapeutic effects on insulin-related diseases, such as diabetes, while alleviating side effects caused by insulin administration, such as weight gain. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 shows the blood glucose regulating effect in type 2 diabetes model mice by combined administration of a long-acting insulin conjugate and a long-acting triple activity conjugate. [Diagram 2] FIG. 1 shows changes in body weight in type 2 diabetes model mice following co-administration of a long-acting insulin conjugate and a long-acting triple activity conjugate. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] One embodiment of the present invention is a composition comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 (glucagon-like peptide-1) receptor, and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

[0020] In one embodiment, the present invention relates to a pharmaceutical composition for preventing or treating an insulin-related disorder comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0021] In another embodiment, the present invention is a pharmaceutical composition for reducing weight gain due to insulin administration, comprising: (i) insulin; and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor, and the GIP receptor.

[0022] In the composition according to any of the above embodiments, the insulin is characterized in that it is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[0023] In any of the above specific examples of the composition, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that it is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[0024] In any of the above specific examples of the composition, the insulin is in the form of a long-acting conjugate bound to a biocompatible substance capable of extending its in vivo half-life, and the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate bound to a biocompatible substance capable of extending its in vivo half-life.

[0025] A composition according to any of the above embodiments, characterized in that the composition is for administration to an individual in need of insulin.

[0026] The composition according to any of the above embodiments, wherein the insulin-related disorder is selected from the group consisting of insulin resistance disorders, diabetes, hyperglycemia and obesity.

[0027] In the composition according to any of the above embodiments, the composition is characterized by having both a blood glucose lowering effect and an effect of suppressing weight gain that occurs when insulin is administered alone.

[0028] In any of the above specific examples of the composition, the composition contains all of insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor, wherein the composition contains insulin or a conjugate thereof:the isolated peptide or a conjugate thereof having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor in a molar ratio of 1:1 to 100:1, or the composition contains insulin or a conjugate thereof:the isolated peptide or a conjugate thereof having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor in a molar ratio of 1:1 to 1:100.

[0029] In a composition according to any of the above specific examples, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that it is a native glucagon analogue having an alteration selected from the group consisting of substitution, addition, deletion, modification and combinations thereof of at least one amino acid of the native glucagon sequence.

[0030] In the composition according to any of the above embodiments, the added amino acid sequence is characterized in that it is derived from the amino acid sequence of native GLP-1, native GIP or native exendin-4.

[0031] In the composition according to any of the above specific examples, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that it is a peptide comprising an amino acid sequence represented by general formula 1.

[0032] Xaa1-Xaa2-Xaa3-Gly-Thr-Phe-Xaa7-Ser-Asp-Xaa10-Ser-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Xaa27-Xaa28-Xaa29-Xaa30-R1 (General formula 1, SEQ ID NO: 103)

[0033] In the general formula 1, Xaa1 is histidine (His, H), 4-imidazoacetyl (CA) or tyrosine (Tyr, Y), Xaa2 is glycine (Gly, G), α-methylglutamic acid or Aib (aminoisobutyric acid), Xaa3 is glutamic acid (Glu, E) or glutamine (Gln, Q), Xaa7 is threonine (Thr, T) or isoleucine (Ile, I), Xaa10 is leucine (Leu, L), tyrosine (Tyr, Y), lysine (Lys, K), cysteine ​​(Cys, C) or valine (Val, V), Xaa12 is lysine (Lys, K), serine (Ser, S) or isoleucine (Ile, I), Xaa13 is glutamine (Gln, Q), tyrosine (T Xaa14 is leucine (Leu, L), methionine (Met, M) or tyrosine (Tyr, Y); Xaa15 is cysteine ​​(Cys, C), aspartic acid (Asp, D), glutamic acid (Glu, E) or leucine (Leu, L); Xaa16 is glycine (Gly, G), glutamic acid (Glu, E) or serine (Ser, S); Xaa17 is glutamine (Gln, Q), arginine (Arg, Xaa18 is alanine (Ala, A), glutamine (Gln, Q), arginine (Arg, R), or histidine (His, H); Xaa19 is alanine (Ala, A), glutamine (Gln, Q), cysteine ​​(Cys, C), or valine (Val, V); Xaa20 is lysine (Lys, K), glutamine (Gln, Q), or arginine (Arg, R), ), Xaa21 is glutamic acid (Glu, E), glutamine (Gln, Q), leucine (Leu, L), cysteine ​​(Cys, C), or aspartic acid (Asp, D), Xaa23 is isoleucine (Ile, I) or valine (Val, V), Xaa24 is alanine (Ala, A), glutamine (Gln, Q), cysteine ​​(Cys, C), asparagine (Asn, N), aspartic acid (Asp, D), or glutamic acid (Glu, E), Xaa27 is valine (Val,Xaa28 is cysteine ​​(Cys, C), lysine (Lys, K), alanine (Ala, A), asparagine (Asn, N), or aspartic acid (Asp, D); Xaa29 is cysteine ​​(Cys, C), glycine (Gly, G), glutamine (Gln, Q), threonine (Thr, T), glutamic acid (Glu, E), or histidine (His, H); Xaa30 is cysteine ​​(Cys, C), lysine (Lys, K), alanine (Ala, A), asparagine (Asn, N), or aspartic acid (Asp, D); Xaa31 is cysteine ​​(Cys, C), glycine (Gly, G), glutamine (Gln, Q), threonine (Thr, T), glutamic acid (Glu, E), or histidine (His, H); R1 is cysteine ​​(Cys,C), glycine (Gly,G), lysine (Lys,K) or histidine (His,H), or is absent, and R1 is cysteine ​​(Cys,C), GKKNDWKHNIT (SEQ ID NO:106), m-SSGAPPPS-n (SEQ ID NO:107) or m-SSGQPPPS-n (SEQ ID NO:108), or is absent, where m is Cys, Pro or Gly-Pro, and n is Cys, Gly, Ser or His-Gly, or is absent.

[0034] A composition according to any of the above embodiments is characterized in that Xaa14 is leucine or methionine and Xaa15 is cysteine, aspartic acid or leucine.

[0035] In the composition according to any of the above embodiments, in general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib, Xaa7 is threonine, Xaa10 is tyrosine, cysteine, or valine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine, glutamine, or cysteine, Xaa14 is leucine, cysteine, or methionine, Xaa15 is cysteine, leucine, glutamic acid, or aspartic acid, Xaa17 is glutamine, arginine, isoleucine, cysteine, Xaa18 is alanine, glutamine, arginine or histidine, Xaa19 is alanine, glutamine, valine or cysteine, Xaa20 is lysine, arginine or glutamine, Xaa21 is glutamic acid, glutamine, leucine, cysteine ​​or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is cysteine, alanine, glutamine, asparagine, glutamic acid or aspartic acid, and Xaa27 is leucine or lysine.

[0036] In the composition according to any of the above specific examples, the peptide is characterized in that it is a peptide comprising an amino acid sequence represented by general formula 2.

[0037] Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Xaa10-Ser-Lys-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa2 1-Phe-Xaa23-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 2, SEQ ID NO: 104)

[0038] In the general formula 2, Xaa1 is 4-imidazoacetyl, histidine or tyrosine, Xaa2 is glycine, α-methylglutamic acid or Aib, Xaa10 is tyrosine or cysteine, Xaa13 is alanine, glutamine, tyrosine or cysteine, Xaa14 is leucine, methionine or tyrosine, Xaa15 is aspartic acid, glutamic acid or leucine, Xaa16 is glycine, glutamic acid or serine, Xaa17 is glutamine, arginine, isoleucine, glutamic acid, cysteine ​​or lysine, Xaa18 is alanine, glutamine, arginine or histidine, and Xaa19 is alanine. , glutamine, cysteine ​​or valine, Xaa20 is lysine, glutamine or arginine, Xaa21 is cysteine, glutamic acid, glutamine, leucine or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is cysteine, alanine, glutamine, asparagine or glutamic acid, Xaa28 is lysine, cysteine, asparagine or aspartic acid, Xaa29 is glycine, glutamine, cysteine ​​or histidine, Xaa30 is cysteine, glycine, lysine or histidine, Xaa31 is proline or cysteine, and Xaa40 is cysteine ​​or absent.

[0039] In the composition according to any of the above embodiments, in general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib, Xaa7 is threonine, Xaa10 is tyrosine, cysteine, or valine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine, or cysteine, Xaa14 is leucine or methionine, Xaa15 is cysteine ​​or aspartic acid, and Xaa17 is glutamine, arginine, Xaa18 is isoleucine, cysteine ​​or lysine, Xaa19 is alanine, glutamine or cysteine, Xaa20 is lysine or glutamine, Xaa21 is glutamic acid, cysteine ​​or aspartic acid, Xaa23 is valine, Xaa24 is alanine, glutamine, cysteine, asparagine or aspartic acid, and Xaa27 is leucine or lysine.

[0040] The composition according to any of the above specific examples is characterized in that, in general formula 2, Xaa13 is alanine, tyrosine or cysteine, Xaa15 is aspartic acid or glutamic acid, Xaa17 is glutamine, arginine, cysteine ​​or lysine, Xaa18 is alanine, arginine or histidine, Xaa21 is cysteine, glutamic acid, glutamine or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is cysteine, glutamine or asparagine, Xaa28 is cysteine, asparagine or aspartic acid, Xaa29 is glutamine, cysteine ​​or histidine, and Xaa30 is cysteine, lysine or histidine.

[0041] In the composition according to any of the above embodiments, in general formula 1, Xaa2 is α-methylglutamic acid or Aib, Xaa7 is threonine, Xaa10 is tyrosine or cysteine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine or cysteine, Xaa14 is leucine or methionine, Xaa15 is cysteine ​​or aspartic acid, Xaa16 is glutamic acid, Xaa17 is arginine, isoleucine, Xaa18 is alanine, arginine or histidine, Xaa19 is alanine, glutamine or cysteine, Xaa20 is lysine or glutamine, Xaa21 is glutamic acid or aspartic acid, Xaa23 is valine, Xaa24 is glutamine, asparagine or aspartic acid, Xaa27 is leucine, and Xaa28 is cysteine, alanine, asparagine or aspartic acid.

[0042] In the composition according to any of the above embodiments, in general formula 1, Xaa1 is histidine or 4-imidazoacetyl, Xaa2 is α-methylglutamic acid or Aib, Xaa3 is glutamine, Xaa7 is threonine, Xaa10 is tyrosine, Xaa12 is isoleucine, Xaa13 is alanine or cysteine, Xaa14 is methionine, Xaa15 is aspartic acid, Xaa16 is glutamic acid, and Xaa17 is isopropyl. Xaa27 is leucine, Xaa28 is alanine or asparagine, Xaa29 is glutamine or threonine, and Xaa30 is cysteine ​​or lysine, or is absent.

[0043] In the composition according to any of the above embodiments, the peptide is characterized in that it is a peptide comprising an amino acid sequence of general formula 3:

[0044] Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Xaa13-Leu-Asp-Glu-Xaa17-Xaa18-Xaa19-Lys-Xaa21-Ph e-Val-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 3, SEQ ID NO: 105)

[0045] In general formula 3, Xaa1 is histidine or tyrosine, Xaa2 is α-methylglutamic acid or Aib, Xaa13 is alanine, tyrosine or cysteine, Xaa17 is arginine, cysteine ​​or lysine, Xaa18 is alanine or arginine, Xaa19 is alanine or cysteine, Xaa21 is glutamic acid or aspartic acid, Xaa24 is glutamine or asparagine, Xaa28 is cysteine ​​or aspartic acid, Xaa29 is cysteine, histidine or glutamine, Xaa30 is cysteine ​​or histidine, Xaa31 is proline or cysteine, and Xaa40 is cysteine ​​or absent.

[0046] In a composition according to any of the above specific examples, R1 is cysteine, GKKNDWKHNIT (SEQ ID NO: 106), CSSGQPPPS (SEQ ID NO: 109), GPSSGAPPPS (SEQ ID NO: 110), GPSSGAPPPSC (SEQ ID NO: 111), PSSGAPPPS (SEQ ID NO: 112), PSSGAPPPSG (SEQ ID NO: 113), PSSGAPPPSHG (SEQ ID NO: 114), PSSGAPPPSS (SEQ ID NO: 115), PSSGQPPPS (SEQ ID NO: 116) or PSSGQPPPSC (SEQ ID NO: 117), or is absent.

[0047] In the composition according to any of the above specific examples, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that it comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 102.

[0048] In a composition according to any of the above embodiments, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that it comprises the amino acid sequence of SEQ ID NO:42.

[0049] In the composition according to any of the above specific examples, the 16th amino acid and the 20th amino acid from the N-terminus in the general formula are characterized in that they form a ring together.

[0050] In any of the above specific examples of the composition, the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is characterized in that its C-terminus is amidated.

[0051] In a composition according to any of the above specific examples, the insulin is characterized in that it is a natural insulin or an insulin analogue in which at least one amino acid of natural insulin has been mutated in a manner selected from the group consisting of substitution, addition, deletion, modification and combinations thereof.

[0052] In the composition according to any of the above specific examples, the insulin analogue is characterized in that at least one amino acid selected from the group consisting of the 1st, 2nd, 3rd, 5th, 8th, 10th, 12th, 16th, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, and 30th amino acids of the B chain and the 1st, 2nd, 5th, 8th, 10th, 12th, 14th, 16th, 17th, 18th, 19th, and 21st amino acids of the A chain of native insulin is substituted with another amino acid, deleted, or mutated by a combination thereof.

[0053] In a composition according to any of the above embodiments, said insulin analogue is characterized in that it comprises an A-chain of SEQ ID NO: 119, represented by general formula 4, and a B-chain of SEQ ID NO: 120, represented by general formula 5.

[0054] [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119)

[0055] In general formula 4, Xaa1 is alanine, glycine, glutamine, histidine, glutamic acid, or asparagine, Xaa2 is alanine or isoleucine, Xaa5 is alanine, glutamic acid, glutamine, histidine, or asparagine, Xaa12 is alanine, serine, glutamine, glutamic acid, histidine, or asparagine, Xaa14 is alanine, tyrosine, glutamic acid, histidine, lysine, aspartic acid, or asparagine, Xaa16 is alanine, leucine, tyrosine, histidine, glutamic acid, or asparagine, Xaa19 is alanine, tyrosine, serine, glutamic acid, histidine, threonine, or asparagine, and Xaa21 is asparagine, glycine, histidine, or alanine.

[0056] [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu-Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120)

[0057] In general formula 5, Xaa8 is alanine or glycine, Xaa16 is tyrosine, glutamic acid, serine, threonine, aspartic acid, or absent, Xaa23 is glycine or alanine, Xaa24 is alanine or phenylalanine, Xaa25 is alanine, phenylalanine, aspartic acid, glutamic acid, or absent, Xaa27 is threonine or absent, and Xaa28 is proline, glutamic acid, aspartic acid, or absent (excluding peptides comprising chain A of SEQ ID NO: 121 and chain B of SEQ ID NO: 122).

[0058] In a composition according to any of the above specific examples, the insulin analogue is characterized in that one amino acid selected from the group consisting of the 8th, 23rd, 24th, and 25th amino acids of the B chain and the 1st, 2nd, and 19th amino acids of the A chain of natural insulin is substituted with alanine, or the 14th amino acid of the A chain is substituted with glutamic acid or asparagine.

[0059] In a composition according to any of the above embodiments, the insulin analogue is characterized in that it comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 126, 128, 130, 132, 134, 136, 138 and 140.

[0060] In a composition according to any of the above specific examples, the insulin analogue is characterized in that the 16th amino acid in the B chain of natural insulin is replaced by glutamic acid, the 25th amino acid is deleted, the 14th amino acid in the A chain of natural insulin is replaced by glutamic acid or alanine, or a combination thereof.

[0061] In a composition according to any of the above embodiments, the insulin analogue is characterized in that it comprises the amino acid sequence of SEQ ID NO: 142 or 144.

[0062] In a composition according to any of the above specific examples, the insulin analogue is characterized in that the 16th amino acid of the B chain of natural insulin is substituted with glutamic acid, serine, threonine or aspartic acid, the 25th amino acid of the B chain of natural insulin is substituted with aspartic acid or glutamic acid, the 14th amino acid of the A chain of natural insulin is substituted with histidine, lysine, alanine or aspartic acid, the 19th amino acid of the A chain of natural insulin is substituted with glutamic acid, serine or threonine, or a combination thereof.

[0063] In a composition according to any of the above embodiments, the insulin analogue is characterized in that it comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168 and 170.

[0064] In a composition according to any of the above specific examples, the insulin analogue is characterized in that it is in the form of a double chain consisting of an A chain of SEQ ID NO: 119, represented by general formula 4, and a B chain of SEQ ID NO: 120, represented by general formula 5.

[0065] The composition according to any of the above embodiments, wherein the A and B chains are linked by a disulfide bond.

[0066] In the composition according to any of the above embodiments, the conjugate is characterized in that it is represented by Chemical Formula 1.

[0067] [Chemical formula 1] X-La-F

[0068] Here, X is an isolated peptide having activity against the insulin or glucagon receptor, the GLP-1 receptor and the GIP receptor, L is a linker, a is 0 or a natural number, provided that each L is independent of the others when a is 2 or more, F is a substance capable of extending the in vivo half-life of X, and the "-" is a covalent or non-covalent bond.

[0069] In any of the above specific examples of the composition, F is characterized in that it is selected from the group consisting of high molecular weight polymers, fatty acids, cholesterol, albumin and fragments thereof, albumin binding substances, polymers of repeating units of specific amino acid sequences, antibodies, antibody fragments, FcRn binding substances, in vivo connective tissue, nucleotides, fibronectin, transferrin, saccharides, heparin, and elastin.

[0070] In any of the above specific examples of the composition, the polymer is characterized in that it is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

[0071] The composition according to any of the above embodiments, wherein F is an immunoglobulin Fc region.

[0072] The composition according to any of the above embodiments, wherein F is an IgG Fc region.

[0073] In a composition according to any of the above embodiments, the immunoglobulin Fc region is characterized in that it is aglycosylated.

[0074] In a composition according to any of the above specific examples, the immunoglobulin Fc region is characterized in that it is selected from the group consisting of: (a) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination of at least one of the CH1 domain, the CH2 domain, the CH3 domain, and the CH4 domain with an immunoglobulin hinge region or a portion of a hinge region; and (f) a dimer of each domain of a heavy chain constant region and a light chain constant region.

[0075] In any of the above specific examples of the composition, the immunoglobulin Fc region is characterized in that it has a disulfide bond-forming site removed, some amino acids at the N-terminus of a native Fc region have been deleted, a methionine residue has been added to the N-terminus of a native Fc region, a complement binding site has been removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site has been removed.

[0076] The composition according to any of the above embodiments, wherein the immunoglobulin Fc region is an immunoglobulin Fc fragment derived from IgG, IgA, IgD, IgE or IgM.

[0077] In a composition according to any of the above specific examples, the immunoglobulin Fc region is characterized in that it is a hybrid of domains of different origin derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE and IgM.

[0078] In the composition according to any of the above specific examples, L is selected from the group consisting of peptides, fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.

[0079] In any of the above specific examples of the composition, the polymer is characterized in that it is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

[0080] In the composition according to any of the above embodiments, L is characterized in that it is polyethylene glycol.

[0081] One embodiment of the present invention is a combination formulation for weight loss in insulin-treated patients, comprising (i) insulin and (ii) isolated peptides having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0082] One embodiment of the present invention is a kit comprising (i) insulin and (ii) isolated peptides having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0083] One aspect of the present invention is the use of said composition in the manufacture of a medicament.

[0084] One embodiment of the present invention is a method for preventing or treating an insulin-related disorder, comprising administering to an individual (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0085] One embodiment of the present invention is a method of reducing weight gain due to insulin administration comprising administering to an individual an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0086] Specifically, one embodiment of the present invention is a method of reducing weight gain due to insulin administration comprising administering to an individual (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0087] The present invention will now be described in more detail.

[0088] In addition, each description and embodiment disclosed in this application is also applicable to other descriptions and embodiments. In other words, all combinations of various elements disclosed in this application are included in the present invention. In addition, the scope of the present invention is not limited to the following specific description.

[0089] Additionally, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the present invention.

[0090] Throughout this specification, the usual one-letter and three-letter codes for naturally occurring amino acids are used, as well as the commonly accepted three-letter codes for other amino acids such as Aib (α-aminoisobutyric acid), Sar (N-methylglycine), α-methyl-glutamic acid, etc. Furthermore, the amino acids referred to herein by abbreviations are written according to the IUPAC-IUB nomenclature system. Alanine Ala,A Arginine Arg,R Asparagine Asn,N Aspartic acid Asp,D Cysteine ​​Cys,C Glutamic acid Glu,E Glutamine Gln,Q Glycine Gly,G Histidine Isoleucine Ile,I Leucine Leu,L Lysine Lys,K Methionine Met,M Phenylalanine Phe,F Proline Pro,P Ser,S Threonine Thr,T Tryptophan Trp,W Tyrosine Tyr,Y Valin,V

[0091] One embodiment of the present invention provides a composition comprising (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 (glucagon-like peptide-1) receptor, and the GIP (glucose-dependent insulinotropic polypeptide) receptor (also referred to as a "triple active agent").

[0092] In one embodiment, the present invention provides a pharmaceutical composition for preventing or treating an insulin-related disorder, comprising: (i) insulin; and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor, and the GIP receptor.

[0093] In another embodiment, the present invention provides a pharmaceutical composition for reducing weight gain due to insulin administration comprising: (i) insulin; and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor, and the GIP receptor.

[0094] Specifically, the composition may comprise (a) insulin and an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor; (b) a long-acting conjugate of insulin, in which insulin is conjugated with a biocompatible substance capable of extending its in vivo half-life, and an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor; (c) a long-acting triple activity conjugate, in which insulin is conjugated with an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor, and a biocompatible substance capable of extending its in vivo half-life; or (d) a long-acting conjugate of insulin and a long-acting triple activity conjugate.

[0095] The pharmaceutical composition of the present invention for preventing or treating insulin-related diseases contains insulin or a long-acting conjugate thereof, and a triple activity form or a long-acting conjugate thereof, and exhibits the pharmacological efficacy of insulin having the preventive or therapeutic effect on insulin-related diseases caused by insulin deficiency, insufficiency or decreased function, while also alleviating side effects (e.g., weight gain) caused by insulin administration.

[0096] In the examples of the present invention, not only was a blood glucose lowering effect confirmed in db / db mice administered a composition containing the insulin or its long-acting conjugate and a triple activity form or its long-acting conjugate, but also a weight gain inhibitory effect was confirmed, demonstrating that the pharmaceutical composition according to the present invention can improve the side effects of insulin while maintaining its efficacy.

[0097] In the present invention, the term "insulin-related disease" refers to a disease caused by an abnormality in the blood glucose regulation function inherent to insulin, such as insulin deficiency, insufficiency, or decreased function, and may be any disease that can be prevented or treated by administration of insulin. Specifically, the insulin-related disease is selected from the group consisting of insulin resistance disease, diabetes, hyperglycemia, and obesity, but is not limited thereto.

[0098] When insulin is administered to treat insulin-related diseases, while the desired therapeutic effect is obtained, there is a problem that unintended side effects such as weight gain occur, which causes further illness and pain to the patient. The pharmaceutical composition according to the present invention can exert a therapeutic effect against insulin-related diseases while suppressing weight gain, which is a side effect of insulin, by using insulin and a triple active compound in combination.

[0099] The composition of the present invention contains insulin or a long-acting conjugate thereof and a triple-active substance or a long-acting conjugate thereof in a content ratio that exhibits a therapeutic effect against insulin-related diseases while alleviating side effects, particularly weight gain.

[0100] Specifically, the composition contains both insulin or a long-acting conjugate thereof and a triple-active agent or a long-acting conjugate thereof, in which the molar ratio of insulin:triple-active agent is 1:1 to 100:1, or 1:1 to 1:100, but is not limited thereto.

[0101] In one embodiment of the present invention, the composition may provide a therapeutic use of insulin or a conjugate thereof in combination with a substance or a conjugate thereof that has activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor. "Insulin" is as described above.

[0102] The "composition" of the present invention is used in combination with a "combination product" containing insulin or a conjugate thereof and a substance active against glucagon receptors, GLP-1 receptors, and GIP receptors. The composition may be provided in the form of a kit.

[0103] The term "combination" in the present invention refers to a combination of insulin or a conjugate thereof with a substance active against the glucagon receptor, the GLP-1 receptor, and the GIP receptor or a conjugate thereof, and is synonymous with "combined used". The combination is a) a mixture of (i) insulin or a conjugate thereof with (ii) a substance active against the glucagon receptor, the GLP-1 receptor, and the GIP receptor or a conjugate thereof, which is administered in a mixed form, or b) a mixture of (i) insulin or a conjugate thereof with (ii) a substance active against the glucagon receptor, the GLP-1 receptor, and the GIP receptor or a conjugate thereof, which is administered in a separated form, but is not limited thereto.

[0104] When insulin or a conjugate thereof and a substance having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor or a conjugate thereof are in a separated form, insulin or a conjugate thereof and a substance having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor or a conjugate thereof may be formulated into separate preparations and administered simultaneously, separately, sequentially or in the reverse order.

[0105] In the present invention, the term "combined administration" should be understood to mean not only simultaneous administration, but also a form of administration in which insulin or a conjugate thereof and a substance or a conjugate thereof having activity against glucagon receptors, GLP-1 receptors, and GIP receptors act together on an individual, and each substance performs a function at a level equal to or higher than its original function. Therefore, in the present application, "combined administration" should be understood to mean simultaneous, separate, sequential, or reversed administration. When the administration is sequential, reversed, or separate, the order of administration is not particularly limited, but the interval between administrations of the secondary components must not lose the advantageous effect of the combination.

[0106] The "composition" in the present invention refers to a combination product itself containing the insulin or a conjugate thereof and a substance or a conjugate thereof active against the glucagon receptor, the GLP-1 receptor, and the GIP receptor, or a combination product containing the same and having therapeutic uses, but is not limited thereto. For example, the composition is used for preventing or treating insulin-related diseases, but is not limited thereto.

[0107] The composition according to the present invention is for co-administration of insulin or a conjugate thereof with a substance active against glucagon receptors, GLP-1 receptors and GIP receptors or a conjugate thereof, and the insulin or a conjugate thereof and the substance active against glucagon receptors, GLP-1 receptors and GIP receptors or a conjugate thereof may be formulated into a single preparation or may be formulated separately. Specifically, the insulin or a conjugate thereof and the substance active against glucagon receptors, GLP-1 receptors and GIP receptors or a conjugate thereof are administered simultaneously, separately, sequentially or in the reverse order, but are not limited thereto.

[0108] The "kit" of the present invention may include a combination product or composition according to the present invention for coadministration of insulin or a conjugate thereof with a substance active against the glucagon receptor, GLP-1 receptor, and GIP receptor, or a conjugate thereof. Specifically, the kit according to the present invention may include a formulation in which insulin or a conjugate thereof and a substance active against the glucagon receptor, GLP-1 receptor, and GIP receptor, or a conjugate thereof, are formulated into one preparation, or a formulation in which insulin or a conjugate thereof and a substance active against the glucagon receptor, GLP-1 receptor, and GIP receptor, or a conjugate thereof, are formulated separately, and may further include a substance necessary for coadministration of the two substances, but is not limited thereto.

[0109] The substances having activity against insulin, glucagon receptors, GLP-1 receptors and GIP receptors include various substances, for example substances in the form of compounds or peptides, that exhibit significant levels of activity against insulin, glucagon receptors, GLP-1 receptors and GIP receptors.

[0110] The "peptide having activity against glucagon receptor, GLP-1 receptor and GIP receptor" in the present invention is used interchangeably with triple-active substance. Meanwhile, the entire texts of Patent Documents 3 and 4 are incorporated herein by reference with respect to triple-active substance and its long-acting conjugate.

[0111] Such triple active agents include various substances, such as various peptides, that have significant levels of activity at the glucagon, GLP-1 and GIP receptors.

[0112] In particular, but not limited to, the triple active substance having a significant level of activity against the glucagon, GLP-1 and GIP receptors has in vitro activity against at least one of the glucagon, GLP-1 and GIP receptors, specifically at least two of the glucagon, GLP-1 and GIP receptors, more specifically against all three of the receptors that is 0.1% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more compared to the natural ligands of the receptors (native glucagon, native GLP-1 and native GIP).

[0113] A method for measuring the in vitro activity of such a triple-active substance is shown in Experimental Example 1 of the present specification, but is not particularly limited thereto.

[0114] On the other hand, the triple-active substance is characterized by having at least one, at least two, specifically three activations, more specifically significant activation, of i) GLP-1 receptor activation, ii) glucagon receptor activation, and iii) GIP receptor activation.

[0115] Here, activating a receptor means, for example, that the in vitro activity against the receptor is 0.1% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more compared to that of a natural receptor, but is not limited thereto.

[0116] Furthermore, the triple activity substance may have a longer half-life in the body than any one of native GLP-1, native glucagon, and native GIP, but is not particularly limited thereto.

[0117] In particular, but without limitation, such peptides are non-naturally occurring.

[0118] Specifically, the triple activity agent is a natural glucagon analog, but is not limited thereto.

[0119] Native glucagon analogs according to the present invention include peptides that have at least one difference in amino acid sequence compared to native glucagon, peptides that have been altered by modification of the native glucagon sequence, and mimetics of native glucagon.

[0120] On the other hand, native glucagon has the following amino acid sequence, although it is not particularly limited thereto:

[0121] His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr (SEQ ID NO: 118)

[0122] Specifically, the triple activity form may be, but is not limited to, an analog of native glucagon having an alteration selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof of at least one amino acid of the native glucagon sequence.

[0123] Furthermore, the amino acid substitution includes all substitutions with amino acids and substitutions with non-natural compounds.

[0124] Furthermore, the addition can be at the N-terminus and / or C-terminus of the triple activity, while the length of the added amino acids can be, but is not limited to, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, and in the broad sense includes, but is not limited to, the addition of a polypeptide.

[0125] The amino acids introduced into the native glucagon are selected from the group consisting of tyrosine, α-methylglutamic acid, Aib, methionine, glutamic acid, histidine, lysine, leucine, isoleucine, glutamine, valine, glycine, alanine, cysteine, serine, aspartic acid and arginine, but are not limited thereto.

[0126] For example, the added amino acid sequence may be one or more amino acid sequences derived from the amino acid sequence of native GLP-1, native GIP, or native exendin-4.

[0127] Such a triple active substance may include an intramolecular bridge (e.g., a covalent or non-covalent bridge), and specifically may be in a form that includes a ring, for example, a ring formed between the 16th and 20th amino acids of the triple active substance, but is not limited thereto.

[0128] Examples of such rings include, but are not limited to, lactam bridges (or lactam rings).

[0129] The triple activity form also includes all those modified to contain a ring by including amino acids that form a ring at the desired position.

[0130] For example, but not limited to, the 16th and 20th amino acid pairs of the triple activator are replaced with ring-forming glutamic acid or lysine, respectively.

[0131] Such a ring may be formed between the amino acid side chains in the triple active compound, for example, but not limited to, a lactam ring formed between the side chains of lysine and glutamic acid.

[0132] Examples of triple activity compounds produced by combining the above methods include, but are not limited to, peptides that have at least one amino acid sequence different from that of native glucagon, have the alpha carbon of the N-terminal amino acid residue removed, and have activity against the glucagon receptor, the GLP-1 receptor, and the GIP receptor. Triple activity compounds for use in the present invention can be produced by combining various methods for producing analogs.

[0133] In addition, although not limited thereto, in the triple activator of the present invention, some of the amino acids can be replaced with other amino acids or non-natural compounds to avoid the recognition action of enzymes that degrade the activator in order to extend the half-life in the body.

[0134] Specifically, the peptide may have an extended half-life in the body by avoiding the recognition action of degradative enzymes through a substitution of the second amino acid sequence in the amino acid sequence of the triple activity form, but any amino acid substitution or modification for avoiding the recognition action of degradative enzymes in the body may be used.

[0135] Such modifications to produce analogs of native glucagon also include modifications with L- or D-amino acids and / or unnatural amino acids, and / or modifications of the native sequence, such as modifications of side chain functional groups, covalent bonds within the molecule, ring formation between side chains, methylation, acylation, ubiquitination, phosphorylation, aminohexylation, biotinylation, and other modifications.

[0136] Further included are all those in which at least one amino acid has been added to the N- and / or C-terminus of native glucagon.

[0137] The substituted or added amino acids can be any of the 20 amino acids commonly found in human proteins, as well as unusual or unnatural amino acids. Commercial sources of unusual amino acids include Sigma-Aldrich, ChemPep, and Genzyme pharmaceuticals. Peptides and typical peptide sequences containing these amino acids can be synthesized and purchased from commercial peptide synthesis companies, such as American Peptide Company and Bachem in the United States, or Anygen in Korea.

[0138] Amino acid derivatives can also be obtained in the same manner, one example being 4-imidazoacetic acid.

[0139] Furthermore, the peptides according to the present invention having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor may be in a form in which the N-terminus and / or the C-terminus, etc. are chemically modified, protected by an organic group, or modified by adding an amino acid to the peptide terminus, etc., in order to protect them from in vivo protein-cleaving enzymes and increase their stability.

[0140] In particular, in the case of chemically synthesized peptides, the N- and C-termini are charged, so that in order to remove the charge, acetylation of the N-terminus and / or amidation of the C-terminus may be performed, but is not limited thereto. Also included is a form in which the C-terminus is not modified, i.e., a form having a carboxy group.

[0141] Furthermore, the peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor according to the present invention, i.e., a triple active substance, is a concept that includes all of the forms of the peptide itself, its salt (e.g., a pharma- ceutically acceptable salt of the peptide) and its solvate. Furthermore, the peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor may be in any form as long as it is pharma- ceutically acceptable.

[0142] The type of the salt is not particularly limited, although it is preferable that the salt is in a form that is safe and effective for an individual, for example, a mammal, but is not particularly limited thereto.

[0143] The term "pharmacologically acceptable" refers to a substance that can be effectively used for a desired purpose without inducing excessive toxicity, irritation, allergic reactions, and the like, within the scope of medical judgment.

[0144] The "pharmaceutically acceptable salt" in the present invention includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, etc. Suitable salts derived from bases include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, ammonium, etc.

[0145] In addition, the term "solvate" in the present invention means a complex formed between the peptide or a salt thereof according to the present invention and a solvent molecule.

[0146] All of the above applies to insulin, which will be described later.

[0147] In a specific embodiment, the peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence represented by general formula 1.

[0148] Xaa1-Xaa2-Xaa3-Gly-Thr-Phe-Xaa7-Ser-Asp-Xaa10-Ser-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Xaa27-Xaa28-Xaa29-Xaa30-R1 (General formula 1, SEQ ID NO: 103)

[0149] In the general formula 1, Xaa1 is histidine, 4-imidazoacetyl or tyrosine, Xaa2 is glycine, α-methylglutamic acid or Aib, Xaa3 is glutamic acid or glutamine, Xaa7 is threonine or isoleucine, Xaa10 is leucine, tyrosine, lysine, cysteine ​​or valine, Xaa12 is lysine, serine or isoleucine, Xaa13 is glutamine, tyrosine, alanine or cysteine, and Xaa14 is rhodamine. Xaa15 is cysteine, aspartic acid, glutamic acid, or leucine; Xaa16 is glycine, glutamic acid, or serine; Xaa17 is glutamine, arginine, isoleucine, glutamic acid, cysteine, or lysine; Xaa18 is alanine, glutamine, arginine, or histidine; Xaa19 is alanine, glutamine, cysteine, or valine; and Xaa20 is lysine, glutamine, or arginine. Xaa21 is glutamic acid, glutamine, leucine, cysteine, or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is alanine, glutamine, cysteine, asparagine, aspartic acid, or glutamic acid, Xaa27 is valine, leucine, lysine, or methionine, Xaa28 is cysteine, lysine, alanine, asparagine, or aspartic acid, and Xaa29 is cysteine, glycine, glutamine, threo Xaa30 is cysteine, glycine, lysine, histidine or absent; R1 is cysteine, GKKNDWKHNIT (SEQ ID NO:106), m-SSGAPPPS-n (SEQ ID NO:107) or m-SSGQPPPS-n (SEQ ID NO:108) or absent, where m is Cys, Pro or Gly-Pro and n is Cys, Gly, Ser, His-Gly or absent.

[0150] Examples of the triple activity include those containing an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 102, and those consisting of an amino acid sequence (essential) selected from the group consisting of SEQ ID NOs: 1 to 102, but are not limited thereto.

[0151] Furthermore, even if the present application describes a "peptide represented by a specific sequence number," this does not exclude meaningless sequence additions, naturally occurring mutations, or silent mutations before or after the amino acid sequence of the sequence number, as long as the peptide has the same or corresponding activity as the peptide consisting of the amino acid sequence of the sequence number, and it goes without saying that those having such sequence additions or mutations are also included in the present application.

[0152] The above also applies to other embodiments or aspects of the present invention, but is not limited thereto.

[0153] Specifically, in General Formula 1, Xaa14 may be leucine or methionine, and Xaa15 may be cysteine, aspartic acid, or leucine. Here, in General Formula 1, the other variables except for Xaa14 and Xaa15 may be a combination of the amino acids described above.

[0154] Examples of such peptides include peptides containing an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, 14 to 17, and 21 to 102, and peptides consisting essentially of these, but are not limited to these.

[0155] These peptides can significantly activate at least one of glucagon receptor, GLP-1 receptor, and GIP receptor, but are not particularly limited thereto. Specifically, they are peptides that significantly activate GLP-1, and further, they are peptides that significantly activate glucagon receptor and / or GIP receptor, but are not particularly limited thereto.

[0156] More specifically, in the general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib, Xaa7 is threonine, Xaa10 is tyrosine, cysteine, or valine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine, glutamine, or cysteine, Xaa14 is leucine, cysteine, or methionine, Xaa15 is cysteine, leucine, glutamic acid, or aspartic acid, Xaa17 is glutamine, arginine, isoleucine, cysteine, glutamic acid, or lysine, and Xaa18 is glycine, arginine, isoleucine, cysteine, glutamic acid, or lysine. The peptide may be, but is not limited to, a peptide in which aa18 is alanine, glutamine, arginine, or histidine, Xaa19 is alanine, glutamine, valine, or cysteine, Xaa20 is lysine, arginine, or glutamine, Xaa21 is glutamic acid, glutamine, leucine, cysteine, or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is cysteine, alanine, glutamine, asparagine, glutamic acid, or aspartic acid, and Xaa27 is leucine or lysine.

[0157] The variables in general formula 1 other than the variables in this embodiment may be combinations of the amino acids described above.

[0158] More specifically, in the general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib, Xaa7 is threonine, Xaa10 is tyrosine, cysteine, or valine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine, or cysteine, Xaa14 is leucine or methionine, Xaa15 is cysteine ​​or aspartic acid, and Xaa17 is glutamine, arginine, isoleucine, cysteine, or is lysine, Xaa18 is alanine, arginine or histidine, Xaa19 is alanine, glutamine or cysteine, Xaa20 is lysine or glutamine, Xaa21 is glutamic acid, cysteine ​​or aspartic acid, Xaa23 is valine, Xaa24 is alanine, glutamine, cysteine, asparagine or aspartic acid, and Xaa27 may be leucine or lysine, but is not limited to these.

[0159] The variables in general formula 1 other than the variables in this embodiment may be combinations of the amino acids described above.

[0160] More specifically, in general formula 1, Xaa2 is α-methylglutamic acid or Aib, Xaa7 is threonine, Xaa10 is tyrosine or cysteine, Xaa12 is lysine or isoleucine, Xaa13 is tyrosine, alanine or cysteine, Xaa14 is leucine or methionine, Xaa15 is cysteine ​​or aspartic acid, Xaa16 is glutamic acid, and Xaa17 is arginine, isoleucine, cysteine, ... Xaa21 may be a glutamic acid or aspartic acid, Xaa23 is valine, Xaa24 is glutamine, asparagine or aspartic acid, Xaa27 is leucine, and Xaa28 is cysteine, alanine, asparagine, or aspartic acid.

[0161] The variables in general formula 1 other than the variables in this embodiment may be combinations of the amino acids described above.

[0162] Specifically, in general formula 1, Xaa1 is histidine or 4-imidazoacetyl, Xaa2 is α-methylglutamic acid or Aib, Xaa3 is glutamine, Xaa7 is threonine, Xaa10 is tyrosine, Xaa12 is isoleucine, Xaa13 is alanine or cysteine, Xaa14 is methionine, Xaa15 is aspartic acid, Xaa16 is glutamic acid, and Xaa17 is isoleucine. Xaa18 is alanine or histidine, Xaa19 is glutamine or cysteine, Xaa20 is lysine, Xaa21 is aspartic acid, Xaa23 is valine, Xaa24 is asparagine, Xaa27 is leucine, Xaa28 is alanine or asparagine, Xaa29 is glutamine or threonine, and Xaa30 is cysteine ​​or lysine or is absent.

[0163] The variables in general formula 1 other than the variables in this embodiment may be combinations of the amino acids described above.

[0164] More specifically, in general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib, Xaa3 is glutamine, Xaa7 is threonine, Xaa10 is tyrosine, cysteine, or valine, Xaa12 is lysine, Xaa13 is tyrosine, Xaa14 is leucine, Xaa15 is aspartic acid, Xaa16 is glycine, glutamic acid, or serine, and Xaa17 is glutamine, arginine, cysteine, or lysine. , Xaa18 is alanine, arginine or histidine, Xaa19 is alanine or glutamine, Xaa20 is lysine or glutamine, Xaa21 is glutamic acid, cysteine ​​or aspartic acid, Xaa23 is valine, Xaa24 is alanine, glutamine or cysteine, Xaa27 is leucine or lysine, and Xaa29 may be glycine, glutamine, threonine or histidine, but is not limited to these.

[0165] The variables in general formula 1 other than the variables in this embodiment may be combinations of the amino acids described above.

[0166] Such a peptide having activity against the glucagon receptor, GLP-1 receptor and GIP receptor may activate the GLP-1 receptor and glucagon receptor to a significant degree and be higher than the degree of activation of the GIP receptor, may activate the GLP-1 receptor, glucagon receptor and GIP receptor to a significant degree and be higher than the degree of activation of the glucagon receptor, may activate all of the GLP-1 receptor, glucagon receptor and GIP receptor to a significant degree and be higher than the degree of activation of the glucagon receptor, but is not limited to these.

[0167] When the activation levels of the GLP-1 receptor and the GIP receptor are significant and higher than that of the glucagon receptor, a peptide having weight loss efficacy and improved blood glucose regulation ability can be provided, and when the activation levels of the GLP-1 receptor, the glucagon receptor, and the GIP receptor are all significant, there is an advantage in that the weight loss effect can be maximized, but is not particularly limited thereto.

[0168] Examples of such peptides include peptides containing an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 9, 21-37, 39, 42, 43, 49-61, 64-83, 85, 86, 88, 89, 91-93, and 95-102, and peptides consisting of these (essential) sequences, but are not particularly limited to these.

[0169] In a specific embodiment, the peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor may comprise an amino acid sequence represented by general formula 2.

[0170] Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Xaa10-Ser-Lys-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa2 1-Phe-Xaa23-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 2, SEQ ID NO: 104)

[0171] In the above formula, Xaa1 is 4-imidazoacetyl, histidine or tyrosine, Xaa2 is glycine, α-methylglutamic acid or Aib, Xaa10 is tyrosine or cysteine, Xaa13 is alanine, glutamine, tyrosine or cysteine, Xaa14 is leucine, methionine or tyrosine, Xaa15 is aspartic acid, glutamic acid or leucine, Xaa16 is glycine, glutamic acid or serine, Xaa17 is glutamine, arginine, isoleucine, glutamic acid, cysteine ​​or lysine, Xaa18 is alanine, glutamine, arginine or histidine, Xaa19 is alanine, Xaa20 is lysine, glutamine or arginine, Xaa21 is cysteine, glutamic acid, glutamine, leucine or aspartic acid, Xaa23 is isoleucine or valine, Xaa24 is cysteine, alanine, glutamine, asparagine or glutamic acid, Xaa28 is lysine, cysteine, asparagine or aspartic acid, Xaa29 is glycine, glutamine, cysteine ​​or histidine, Xaa30 is cysteine, glycine, lysine or histidine, Xaa31 is proline or cysteine, and Xaa40 is cysteine ​​or absent.

[0172] More specifically, in general formula 2, Xaa13 may be alanine, tyrosine or cysteine, Xaa15 may be aspartic acid or glutamic acid, Xaa17 may be glutamine, arginine, cysteine ​​or lysine, Xaa18 may be alanine, arginine or histidine, Xaa21 may be cysteine, glutamic acid, glutamine or aspartic acid, Xaa23 may be isoleucine or valine, Xaa24 may be cysteine, glutamine or asparagine, Xaa28 may be cysteine, asparagine or aspartic acid, Xaa29 may be glutamine, cysteine ​​or histidine, and Xaa30 may be cysteine, lysine or histidine.

[0173] The variables of general formula 2 other than the variables in this embodiment may be combinations of the amino acids described above.

[0174] Examples of peptides having activity against such glucagon receptors, GLP-1 receptors and GIP receptors include, but are not limited to, amino acid sequences selected from the group consisting of SEQ ID NOs: 21, 22, 42, 43, 50, 64 to 77, and 95 to 102, more specifically, peptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs: 21, 22, 42, 43, 50, 64 to 77, and 96 to 102, and peptides consisting of these (essential) components.

[0175] In a specific embodiment, the peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor may comprise an amino acid sequence of general formula 3:

[0176] Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Xaa13-Leu-Asp-Glu-Xaa17-Xaa18-Xaa19-Lys-Xaa21-Ph e-Val-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 3, SEQ ID NO: 105)

[0177] In general formula 3, Xaa1 is histidine or tyrosine, Xaa2 is α-methylglutamic acid or Aib, Xaa13 is alanine, tyrosine or cysteine, Xaa17 is arginine, cysteine ​​or lysine, Xaa18 is alanine or arginine, Xaa19 is alanine or cysteine, Xaa21 is glutamic acid or aspartic acid, Xaa24 is glutamine or asparagine, Xaa28 is cysteine ​​or aspartic acid, Xaa29 is cysteine, histidine or glutamine, Xaa30 is cysteine ​​or histidine, Xaa31 is proline or cysteine, and Xaa40 is cysteine ​​or absent.

[0178] Examples of peptides having activity against such glucagon receptors, GLP-1 receptors, and GIP receptors include peptides containing an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 22, 42, 43, 50, 64-71, 75-77, and 96-102, and peptides consisting of these (essential) sequences, but are not limited to these.

[0179] In addition, in general formula 1, R1 is cysteine, GKKNDWKHNIT (sequence number 106), CSSGQPPPS (sequence number 109), GPSSGAPPPS (sequence number 110), GPSSGAPPPSC (sequence number 111), PSSGAPPPS (sequence number 112), PSSGAPPPSG (sequence number 113), PSSGAPPPSHG (sequence number 114), PSSGAPPPSS (sequence number 115), PSSGQPPPS (sequence number 116) or PSSGQPPPSC (sequence number 117), or is absent, but is not limited to these.

[0180] Furthermore, depending on the length, the peptides of the present invention can be synthesized by methods well known in the art, for example, by an automatic peptide synthesizer, or can be produced by genetic engineering techniques.

[0181] Specifically, the peptides of the present invention can be produced by standard synthesis methods, recombinant expression systems, or any other method known in the art. Thus, the peptides of the present invention can be synthesized in a number of ways, including, for example, (a) synthesizing the peptide stepwise in solid or liquid phase methods or by fragment assembly, and isolating and purifying the final peptide product, (b) expressing a nucleic acid construct encoding the peptide in a host cell and recovering the expression product from the host cell culture, (c) expressing a nucleic acid construct encoding the peptide in a cell-free test tube and recovering the expression product, or recovering fragments of the peptide by any combination of (a), (b), and (c), and then ligating the fragments to obtain the peptide, thereby recovering the peptide.

[0182] In the present invention, "insulin" refers to a type of hormone secreted from pancreatic β cells, and generally plays a role in promoting glucose uptake into cells, inhibiting fat decomposition, and regulating blood glucose in the body. Insulin is converted to insulin having blood glucose regulating function through processing from the form of a proinsulin precursor that does not have blood glucose regulating function. Insulin consists of two polypeptide chains, namely, A chain and B chain, which contain 21 and 30 amino acid residues, respectively, and are linked to each other by two disulfide bridges. The insulin may be human insulin. The A chain and B chain of natural human insulin contain the amino acid sequences shown in SEQ ID NOs: 121 and 122, respectively.

[0183] A chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID NO: 121)

[0184] B chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (SEQ ID NO: 122)

[0185] In the present invention, "proinsulin" refers to a precursor molecule of insulin. The proinsulin may include insulin A and B chains and a C-peptide therebetween. The proinsulin may be human proinsulin.

[0186] The insulin in the present invention may be a naturally occurring insulin, or an analog, derivative, or fragment in which at least one amino acid of naturally occurring insulin has been mutated in a manner selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof, but is not limited thereto.

[0187] In the present invention, the term "insulin analog" refers to a non-natural insulin that is different from natural insulin.

[0188] The insulin analogues include those modified by addition, deletion or substitution of some amino acids of natural insulin. For example, the insulin analogues may be those in which at least one amino acid selected from the group consisting of the 1st, 2nd, 3rd, 5th, 8th, 10th, 12th, 16th, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, and 30th amino acids of the B chain and the 1st, 2nd, 5th, 8th, 10th, 12th, 14th, 16th, 17th, 18th, 19th, and 21st amino acids of the A chain of natural insulin is substituted with another amino acid or deleted, but are not limited thereto. The insulin analogues of the present invention are disclosed in Patent Document 5 or 6 (or Patent Documents 1 and 2), the entire texts of which are incorporated herein by reference.

[0189] The insulin analogue used in the present invention may be in the form of a single chain or a double chain (two polypeptide chains), and the double chain form is more preferable, but is not limited thereto. The double chain may be composed of two polypeptides, a polypeptide corresponding to the A chain of natural insulin and a polypeptide corresponding to the B chain of natural insulin. Here, the one corresponding to the A chain or B chain of natural insulin means, when comparing the sequence identity of either one of the chains of the double chain polypeptide with the A chain or B chain of natural insulin, that has at least 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, or 95% or more of sequence identity, but is not limited thereto, and can be easily understood by a person skilled in the art by comparing the sequence constituting the double chain with the sequence of the A chain or B chain of natural insulin.

[0190] In the present invention, "homology" refers to the degree of similarity to the amino acid sequence of a wild type protein or the nucleotide sequence encoding the same, and includes sequences having a sequence that is identical to the amino acid sequence or nucleotide sequence of the present invention by the above percentage or more. Such homology can be determined by visually comparing two sequences, or by using a bioinformatics algorithm that aligns the sequences to be compared and analyzes the degree of homology. The homology between the two amino acid sequences is expressed as a percentage. Useful automated algorithms can be found in the GAP, BESTFIT, FASTA, and TFASTA computer software modules of the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, W, USA). Algorithms automated in the modules include Needleman & Wunsch, Pearson & Lipman, and Smith & Waterman sequence alignment algorithms. Other useful algorithms for sequence and homology determination are automated in software including FASTP, BLAST, BLAST2, PSIBLAST, and CLUSTAL W.

[0191] Information on the insulin sequence used in the present invention and the nucleotide sequence encoding it can be obtained from known databases such as NCBI.

[0192] In one specific embodiment, the insulin analogue of the invention is a composition comprising an A-chain of SEQ ID NO: 119, represented by the general formula 4, and a B-chain of SEQ ID NO: 120, represented by the general formula 5.

[0193] [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119)

[0194] In general formula 4, Xaa1 is alanine, glycine, glutamine, histidine, glutamic acid, or asparagine, Xaa2 is alanine or isoleucine, Xaa5 is alanine, glutamic acid, glutamine, histidine, or asparagine, Xaa12 is alanine, serine, glutamine, glutamic acid, histidine, or asparagine, Xaa14 is alanine, tyrosine, glutamic acid, histidine, lysine, aspartic acid, or asparagine, Xaa16 is alanine, leucine, tyrosine, histidine, glutamic acid, or asparagine, Xaa19 is alanine, tyrosine, serine, glutamic acid, histidine, threonine, or asparagine, and Xaa21 is asparagine, glycine, histidine, or alanine.

[0195] [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu-Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120)

[0196] In general formula 5, Xaa8 is alanine or glycine, Xaa16 is tyrosine, glutamic acid, serine, threonine, aspartic acid, or absent, Xaa23 is glycine or alanine, Xaa24 is alanine or phenylalanine, Xaa25 is alanine, phenylalanine, aspartic acid, glutamic acid, or absent, Xaa27 is threonine or absent, and Xaa28 is proline, glutamic acid, aspartic acid, or absent (excluding peptides comprising chain A of SEQ ID NO: 121 and chain B of SEQ ID NO: 122).

[0197] More specifically, the insulin analogue may have one amino acid selected from the group consisting of the 8th, 23rd, 24th and 25th amino acids of the B chain and the 1st, 2nd and 19th amino acids of the A chain of natural insulin substituted with alanine and / or the 14th amino acid of the A chain substituted with glutamic acid or asparagine, in particular comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 126, 128, 130, 132, 134, 136, 138 and 140, but is not limited thereto.

[0198] The insulin analogues also have the 16th amino acid of the B chain of natural insulin substituted with glutamic acid and / or the 25th amino acid deleted and / or the 14th amino acid of the A chain of natural insulin substituted with glutamic acid or alanine, and in particular comprise or consist of the amino acid sequence of SEQ ID NO: 142 or 144, but are not limited thereto.

[0199] The insulin analogue may also have the 16th amino acid of the B chain of natural insulin substituted with glutamic acid, serine, threonine or aspartic acid, and / or the 25th amino acid substituted with aspartic acid or glutamic acid, and / or the 14th amino acid of the A chain of natural insulin substituted with histidine, lysine, alanine or aspartic acid, and / or the 19th amino acid substituted with glutamic acid, serine or threonine, in particular comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168 and 170, but is not limited thereto.

[0200] The insulin analogue of the present invention may be in the form of a single-chain insulin from which the C-peptide has not been removed, and may be a substance that contains an A chain of SEQ ID NO: 119 and represented by general formula 4, and a B chain of SEQ ID NO: 120 and represented by general formula 5, and has the activity and function of insulin.

[0201] The insulin analogue of the present invention may also be prepared by removing the C-peptide from proinsulin containing the C-peptide between the A-chain and the B-chain. The C-peptide can be removed by a method known in the art, specifically, by treatment with trypsin and carboxypeptidase B, but is not limited thereto.

[0202] Specifically, the insulin analogue of the present invention may be composed of an A-chain of SEQ ID NO: 119, represented by general formula 4, and a B-chain of SEQ ID NO: 120, represented by general formula 5, or more specifically, a double-chain insulin form in which the A-chain and B-chain are linked to each other by two disulfide bridges, but is not limited thereto.

[0203] Needless to say, the present invention also includes insulin analogs produced in a double-chain form by removing the C-peptide from an insulin analog in the proinsulin form represented by a specific sequence number.

[0204] Specifically, the insulin analogue has the following amino acid modifications in the sequence of natural insulin, particularly natural human insulin, and is selected from analogues 1 to 24 in Table 4.

[0205] TIFF0007596268000001.tif185149

[0206] The "insulin derivative" in the present invention includes a peptide having at least one difference in the amino acid sequence compared to natural insulin, a peptide altered by modifying the natural insulin sequence, and a natural insulin mimic that regulates blood glucose in vivo like natural insulin. This derivative of natural insulin may have the function of regulating blood glucose in vivo.

[0207] Specifically, insulin derivatives may be insulin in which some amino acids of natural insulin have been altered by any one of substitution, addition, deletion and modification, or a combination of these methods.

[0208] Specifically, it may be in a form that shows at least 80% amino acid sequence homology with the A-chain and B-chain of natural insulin, respectively, and / or in which some groups of one of the amino acid residues of insulin have been chemically substituted (e.g., alpha-methylation, alpha-hydroxylation), removed (e.g., deamination) or modified (e.g., N-methylation), but is not limited to these.

[0209] Derivatives of natural insulin for use in the present invention can be produced by a combination of various methods for producing derivatives.

[0210] Furthermore, such modifications for the production of insulin derivatives include all modifications using L- or D-amino acids and / or unnatural amino acids, and / or modifications by modifying the native sequence or post-translational modifications (e.g., methylation, acylation, ubiquitination, intramolecular covalent bonds, etc.).

[0211] Furthermore, insulin having one or more amino acids added to the N- and / or C-terminus is all included.

[0212] The substituted or added amino acids can be any of the 20 amino acids commonly found in human proteins, as well as unusual or unnatural amino acids. Commercial sources of unusual amino acids include Sigma-Aldrich, ChemPep, and Genzyme pharmaceuticals. Peptides and typical peptide sequences containing these amino acids can be synthesized and purchased from private peptide synthesis companies, such as American Peptide Company and Bachem in the United States, or Anygen in Korea, but are not limited thereto.

[0213] In the present invention, the term "fragment of natural insulin, insulin analogue or insulin derivative" refers to a form in which at least one amino acid is deleted at the N-terminus or C-terminus of natural insulin, insulin analogue or derivative of natural insulin. Such fragments have a blood glucose regulating function in the body.

[0214] The insulin analogues of the present invention may be produced using any of the methods used for producing the above-mentioned derivatives and fragments of natural insulin, either alone or in combination.

[0215] Specifically, insulin analogues according to the present invention include those in which specific amino acid residues in the A-chain and B-chain of such natural insulin have been modified, and more specifically, may be those in which specific amino acid residues in the A-chain and / or specific amino acid residues in the B-chain of natural insulin have been modified.

[0216] The pharmaceutical composition according to the present invention may contain insulin as one of the active ingredients, which may be (a) natural insulin, (b) an insulin analogue, (c) an insulin derivative, (d) a fragment thereof, or (e) a combination thereof, so long as it has the blood glucose regulating ability of insulin.

[0217] In one embodiment, the insulin of the present invention, or an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor, may be in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[0218] In the present invention, a "long-acting conjugate" or "conjugate" of an isolated peptide having activity on insulin, or the glucagon receptor, the GLP-1 receptor and the GIP receptor means a conjugate having a structure in which an insulin, or an isolated peptide having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor is conjugated to a biocompatible substance, and which has improved duration of efficacy compared to insulin, or an isolated peptide having activity on the glucagon receptor, the GLP-1 receptor and the GIP receptor that is not conjugated to the biocompatible substance.

[0219] The biocompatible substance in the long-acting conjugate may be, but is not limited to, a covalently linked peptide having activity against insulin or glucagon receptors, GLP-1 receptors, and GIP receptors.

[0220] In the present invention, insulin, which is one component of the conjugate, may be insulin having a native sequence, or an analog, derivative, or fragment of insulin in which at least one amino acid in the native sequence has been mutated by substitution, addition, deletion, modification, or a combination thereof, but any insulin may be used as one component of the conjugate of the present invention as long as it has the blood glucose lowering / increasing effect of native insulin.

[0221] In the present invention, the term "biocompatible substance" refers to a substance that is bound to a physiologically active substance (e.g., isolated peptides having activity against glucagon receptors, GLP-1 receptors and GIP receptors, insulin, etc.) and can improve the duration of the effect of the physiologically active substance compared to a physiologically active substance that is not bound to a biocompatible substance moiety or carrier. The biocompatible substance may be linked to the physiologically active substance by a covalent bond, but is not particularly limited thereto.

[0222] Specifically, the conjugate is represented by Chemical Formula 1.

[0223] [Chemical formula 1] X-La-F

[0224] wherein X is the insulin or isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor (i.e., a triple active compound); L is a linker; a is 0 or a natural number, provided that each L is independent of the others as long as a is 2 or more; and F is a substance capable of extending the half-life of X.

[0225] The composition of the present invention may comprise (a) insulin and a triple activity form, (b) a long-acting conjugate of insulin and a triple activity form, (c) insulin and a long-acting conjugate of the triple activity form, or (d) a long-acting conjugate of insulin and a long-acting conjugate of the triple activity form, and the insulin or triple activity form in the form of a long-acting conjugate exhibits excellent blood glucose regulating effects due to improved persistence in the body and can ameliorate the side effects of insulin.

[0226] F in said conjugate is a substance capable of increasing the half-life of X, insulin or a triple active agent, and is an integral part of said conjugate of the invention.

[0227] The F's may be bonded to X by a covalent or non-covalent chemical bond, or may be bonded to X via L by a covalent or non-covalent chemical bond, or a combination thereof.

[0228] The substance capable of extending the half-life of X may be a biocompatible substance, such as, but not limited to, a polymer, a fatty acid, cholesterol, albumin and fragments thereof, an albumin-binding substance, a polymer of repeating units of a specific amino acid sequence, an antibody, an antibody fragment, an FcRn-binding substance, in vivo connective tissue, a nucleotide, fibronectin, transferrin, saccharide, heparin, and elastin.

[0229] In the case of elastin, it may be human tropoelastin, which is a water-soluble precursor, or it may be a polymer of a partial sequence or a partial repeating unit thereof, for example, an elastin-like polypeptide, but is not limited to these.

[0230] Examples of the polymer include, but are not limited to, polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

[0231] The polyethylene glycol includes, but is not limited to, ethylene glycol homopolymers, PEG copolymers, and monomethyl-substituted PEG polymers (mPEG).

[0232] The biocompatible material also includes polyamino acids such as polylysine, polyaspartic acid, and polyglutamic acid, but is not limited to these.

[0233] Furthermore, the fatty acid has a binding ability to albumin in the body, but is not particularly limited thereto.

[0234] As a more specific example, the FcRn-binding substance is an immunoglobulin Fc region, and more specifically, an IgG Fc region, but is not particularly limited thereto.

[0235] At least one amino acid side chain in the peptides of the invention may be conjugated to such biocompatible substances to improve solubility and / or half-life in vivo and / or increase bioavailability. Such modifications also reduce the clearance of therapeutic proteins and peptides.

[0236] The biocompatible materials mentioned above may be water-soluble (amphiphilic or hydrophilic) and / or non-toxic and / or pharma- ceutical acceptable.

[0237] The F may be directly linked to X (ie, in Chemical Formula 1, a is 0) or may be linked to X via a linker L.

[0238] In the present invention, the "immunoglobulin Fc region" refers to a portion excluding the variable regions of the heavy and light chains of an immunoglobulin and including the heavy chain constant region 2 (CH2) and / or the heavy chain constant region 3 (CH3). The immunoglobulin Fc region is a component that forms a part of the conjugate of the present invention.

[0239] Such an immunoglobulin Fc region may include a hinge region in the heavy chain constant region, but is not limited thereto. Furthermore, the immunoglobulin Fc region of the present invention may be an extended Fc region including a part or the whole of heavy chain constant region 1 (CH1) and / or light chain constant region 1 (CL1) excluding the variable regions of the heavy and light chains of an immunoglobulin, so long as it has an effect substantially equivalent to or improved from that of a natural one. Furthermore, it may be a region in which a very long part of the amino acid sequence corresponding to CH2 and / or CH3 is deleted.

[0240] For example, the immunoglobulin Fc region of the present invention is 1) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of at least one of the CH1 domain, the CH2 domain, the CH3 domain, and the CH4 domain with an immunoglobulin hinge region (or a part of the hinge region), or 6) a dimer of each domain of a heavy chain constant region and a light chain constant region, but is not limited thereto.

[0241] In addition, as a specific example, the immunoglobulin Fc region may be in a dimeric form, and may have one X1 molecule covalently linked to one Fc region in the dimeric form, where the immunoglobulin Fc and X may be linked to each other via a non-peptidic polymer. On the other hand, the immunoglobulin Fc region in the dimeric form may have one X2 molecule symmetrically linked to it. Here, the immunoglobulin Fc and X may be linked to each other via a non-peptidic linker. However, the present invention is not limited thereto.

[0242] Furthermore, the immunoglobulin Fc region of the present invention includes not only naturally occurring amino acid sequences but also sequence derivatives thereof. An amino acid sequence derivative means a sequence in which at least one amino acid residue of the naturally occurring amino acid sequence is different due to deletion, insertion, non-conservative or conservative substitution, or a combination thereof.

[0243] For example, in the case of IgG Fc, amino acid residues at positions 214 to 238, 297 to 299, 318 to 322, or 327 to 331, which are known to be important for binding, may be used as sites suitable for modification.

[0244] Also, various kinds of derivatives are used, such as derivatives in which the site forming disulfide bonds has been removed, derivatives in which several amino acids have been deleted from the N-terminus of native Fc, or derivatives in which a methionine residue has been added to the N-terminus of native Fc. Furthermore, in order to eliminate effector functions, complement binding sites, such as C1q binding sites, and ADCC (antibody dependent cell mediated cytotoxicity) sites may be removed. Techniques for producing such sequence derivatives of immunoglobulin Fc regions are disclosed in Patent Documents 7 and 8, etc.

[0245] Amino acid exchanges in proteins and peptides that do not change the overall activity of the molecule are known in the art (Non-Patent Document 1). The most common exchanges are between the amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly. In some cases, the amino acid residues may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation, etc.

[0246] The above-mentioned Fc derivatives may exhibit biological activity equivalent to that of the Fc region of the present invention, and may have improved structural stability against heat, pH, and the like of the Fc region.

[0247] In addition, such an Fc region may be obtained from a natural source isolated from the living body of an animal such as a human or a cow, a goat, a pig, a mouse, a rabbit, a hamster, a rat, or a guinea pig, or may be a recombinant product obtained from a transformed animal cell or a microorganism, or a derivative thereof. Here, the method of obtaining from a natural source may be a method of obtaining by isolating the whole immunoglobulin from the living body of a human or an animal and then treating it with a protease. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab)2. These can be separated into Fc or pF'c using size-exclusion chromatography or the like. In a more specific embodiment, the human-derived Fc region is a recombinant immunoglobulin Fc region obtained from a microorganism.

[0248] Furthermore, the immunoglobulin Fc region may be in a form having a natural sugar chain, an increased sugar chain compared to the natural one, a decreased sugar chain compared to the natural one, or a form in which the sugar chain has been removed. For increasing, decreasing, or removing such immunoglobulin Fc sugar chains, conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms are used. Here, an immunoglobulin Fc region from which the sugar chains have been removed from Fc has a significantly reduced binding ability to complement (c1q) and antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity is reduced or removed, so that it does not induce unnecessary immune reactions in vivo. For these reasons, an immunoglobulin Fc region from which the sugar chains have been removed or which has been deglycosylated is suitable for its original purpose as a drug carrier.

[0249] In the present invention, "deglycosylation" refers to an Fc region from which sugar chains have been removed using an enzyme, and "non-glycosylated" refers to an Fc region that is produced in a prokaryote, or in a more specific embodiment, in Escherichia coli, and is not glycosylated.

[0250] On the other hand, the immunoglobulin Fc region may be of human origin or animal origin, such as bovine, goat, porcine, murine, rabbit, hamster, rat, guinea pig, and in a more specific embodiment is of human origin.

[0251] Moreover, the immunoglobulin Fc region is derived from IgG, IgA, IgD, IgE, IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which are the most abundant in human blood, and in an even more specific embodiment, it is derived from IgG, which is known to extend the half-life of ligand-binding proteins. In an even more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in a most specific embodiment, the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4, but is not limited thereto.

[0252] On the other hand, the term "combination" in the present invention means that, when a dimer or multimer is formed, a polypeptide encoding a single-chain immunoglobulin Fc region of the same origin is bound to a single-chain polypeptide of a different origin, i.e., a dimer or multimer can be prepared from at least two fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc, and IgE Fc fragments.

[0253] The conjugates described above may also have improved durability of efficacy compared to native insulin or triply active forms, or to X where F is unmodified, and such conjugates include not only the forms described above, but also those encapsulated in biodegradable nanoparticles, etc.

[0254] Furthermore, the L may be a peptidic linker or a non-peptidic linker.

[0255] When the L is a peptidic linker, it contains one or more amino acids, for example, 1 to 1000 amino acids, but is not limited thereto. In the present invention, various known peptide linkers are used to link F and X, for example, [GS]x linker, [GGGS]x linker, [GGGGS]x linker, etc., where x is a natural number of 1 or more. However, it is not limited to the above examples.

[0256] The "non-peptidic linker" of the present invention includes a biocompatible polymer having at least two repeating units bonded together. The repeating units are linked to each other by any covalent bond except a peptide bond. The non-peptidic linker is a part of the conjugate of the present invention and corresponds to L in Chemical Formula 1. The non-peptidic linker of the present invention is used in combination with a non-peptidic polymer.

[0257] The non-peptidic linker in the present invention contains a reactive group at its terminal and can form a conjugate by reacting with other components constituting the conjugate. When a non-peptidic linker having reactive functional groups at both terminals forms a conjugate by binding to X and F in Chemical Formula 1 via each reactive group, the non-peptidic linker or non-peptidic polymer is also called a non-peptidic linker linking moiety or a non-peptidic polymer linking moiety.

[0258] In the above La, a may be 1 or more, and when a is 2 or more, each L may be independent.

[0259] In a specific embodiment, the conjugate may be one in which F and X are covalently linked to each other via a non-peptide linker comprising reactive groups at both ends that are coupled to F, specifically an immunoglobulin Fc region, and X, specifically a peptide drug.

[0260] Specifically, the non-peptide linker may be selected from the group consisting of fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.

[0261] The molecular weight of the polymer in the present invention is in the range of more than 0 and not more than about 100 kDa, specifically in the range of about 1 to about 100 kDa, and more specifically in the range of about 1 to about 20 kDa, but is not particularly limited thereto.

[0262] In the present invention, "about" refers to a range that includes ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all numerical values ​​that are equal to or in a similar range to the numerical value following the term "about," but is not limited to these.

[0263] The polymer may be selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof, but is not limited thereto. In a more specific embodiment, the L is polyethylene glycol, but is not limited thereto. In addition, the present invention also includes derivatives thereof known in the art and derivatives that can be easily prepared at the technical level of the art.

[0264] The non-peptidyl linker used in the present invention may be any polymer that is resistant to endogenous proteases. The molecular weight of the non-peptidyl polymer is in the range of about 1 to about 100 kDa, specifically about 1 to about 20 kDa, but is not limited thereto. Furthermore, the non-peptidyl linker of the present invention that is bound to the polypeptide corresponding to F may be not only one type of polymer, but also a combination of different types of polymers.

[0265] In a specific embodiment, both ends of the non-peptidic linker can be bound to an amino or thiol group of F, for example an immunoglobulin Fc region, and an amino or thiol group of X, respectively.

[0266] Specifically, the non-peptidyl polymer contains reactive groups at both ends that are bonded to F (e.g., an immunoglobulin Fc region) and X, respectively, specifically, reactive groups that are bonded to X, or an amino group located at the N-terminus or lysine of F (e.g., an immunoglobulin Fc region), or a thiol group of cysteine, but are not limited thereto.

[0267] Furthermore, the reactive group of the non-peptidyl polymer bound to F, for example, an immunoglobulin Fc region, and X is selected from the group consisting of an aldehyde group, a maleimide group, and a succinimide derivative, but is not limited thereto.

[0268] In the above, examples of the aldehyde group include, but are not limited to, a propionaldehyde group or a butyraldehyde group.

[0269] In the above, examples of succinimide derivatives include, but are not limited to, succinimidyl valerate, succinimidyl methyl butanoate, succinimidyl methyl propionate, succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccinimide, hydroxysuccinimidyl, succinimidyl carboxymethyl, and succinimidyl carbonate.

[0270] The non-peptide linker is linked to X and F via such a reactive group, but is not particularly limited thereto.

[0271] Furthermore, the final products generated by reductive amination with aldehyde bonds are much more stable than those linked with amide bonds. The aldehyde reactive group selectively reacts with the N-terminus at low pH and can form covalent bonds with lysine residues at high pH, ​​e.g., pH 9.0.

[0272] The reactive groups at both ends of the non-peptidic linker may be the same or different. For example, one end may have a maleimide group and the other end may have an aldehyde group, a propionaldehyde group, or a butyraldehyde group. However, the non-peptidic linker is not particularly limited to these, as long as F, specifically, the immunoglobulin Fc region and X are bonded to each end of the non-peptidic linker.

[0273] For example, the non-peptide linker may contain a maleimide group as a reactive group at one end and an aldehyde group, a propionaldehyde group, a butyraldehyde group, or the like at the other end.

[0274] When polyethylene glycol having hydroxy reactive groups at both ends is used as the non-peptidic polymer, the hydroxy groups can be activated into the various reactive groups described above by known chemical reactions, or a commercially available polyethylene glycol having modified reactive groups can be used to prepare the long-acting protein conjugate of the present invention.

[0275] In a specific embodiment, the non-peptidyl polymer is linked to a cysteine ​​residue of the triply active moiety, more specifically, but not limited to, a -SH group of cysteine.

[0276] Examples of the triple activity form include, but are not limited to, those in which the non-peptidyl polymer is linked to the 10th cysteine ​​residue, the 13th cysteine ​​residue, the 15th cysteine ​​residue, the 17th cysteine ​​residue, the 19th cysteine ​​residue, the 21st cysteine ​​residue, the 24th cysteine ​​residue, the 28th cysteine ​​residue, the 29th cysteine ​​residue, the 30th cysteine ​​residue, the 31st cysteine ​​residue, the 40th cysteine ​​residue, or the 41st cysteine ​​residue.

[0277] Specifically, the reactive group of the non-peptidyl polymer may be linked to the -SH group of the cysteine ​​residue. The reactive group is as described above. When maleimide-PEG-aldehyde is used, the maleimide group can be linked to the -SH group of X by a thioether bond, and the aldehyde group can be linked to F, specifically, the -NH2 group of immunoglobulin Fc by a reductive amination reaction, but these are merely examples and are not limited thereto.

[0278] In a specific embodiment, the non-peptidyl polymer may be linked to an amino group of insulin or an analog thereof, more specifically, an amino group located at the N-terminus or an amino group located at a side chain of lysine, but is not limited thereto, and these are merely examples.

[0279] Furthermore, in the above-mentioned conjugate, the reactive group of the non-peptidyl polymer may be linked to -NH2 located at the N-terminus of the immunoglobulin Fc region, but this is merely one example.

[0280] In the present invention, "prevention" means any action of suppressing or delaying the onset of an insulin-related disease by administering the composition, and "treatment" means any action of improving or favorably changing the symptoms of an insulin-related disease by administering the composition.

[0281] In the present invention, "administration" means introducing a predetermined substance into a patient by any appropriate method, and the administration route of the composition is not particularly limited, but may be any common route that can deliver the composition to an in vivo target, such as intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, pulmonary administration, and rectal administration.

[0282] The pharmaceutical composition according to the present invention may include a pharma- ceutically acceptable carrier.

[0283] In the present invention, "pharmacologically acceptable" means a sufficient amount to exert a therapeutic effect and to cause no side effects, and can be easily determined by a person skilled in the art based on factors known in the medical field, such as the type of disease, the patient's age, weight, health condition, sex, sensitivity to the drug, administration route, administration method, number of doses, treatment period, combination, and drugs used concomitantly.

[0284] The pharma- ceutically acceptable carrier may be a binder, lubricant, disintegrant, excipient, solubilizer, dispersant, stabilizer, suspending agent, dye, flavoring, etc., for oral administration, a buffer, preservative, soothing agent, solubilizer, isotonic agent, stabilizer, etc., for injection, a base, excipient, lubricant, preservative, etc., for topical administration. The pharmaceutical composition of the present invention may be prepared in various forms by mixing with the pharma-ceutically acceptable carrier as described above. For example, for oral administration, it may be prepared in the form of tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, etc., and for injection, it may be prepared in the form of disposable ampoules or multiple doses. It may also be prepared in the form of solutions, suspensions, tablets, pills, capsules, sustained release preparations, etc.

[0285] Examples of carriers, excipients, and diluents suitable for formulation include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. Furthermore, the formulation may further contain a filler, an anti-agglomerating agent, a lubricant, a wetting agent, a flavoring, an emulsifier, a preservative, etc.

[0286] Furthermore, the pharmaceutical composition of the present invention may have any dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral liquids, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, lyophilized agents, and suppositories.

[0287] Furthermore, the conjugate can be used by mixing it with various medicament-acceptable carriers such as physiological saline or organic solvents, and in order to improve stability and water absorption, carbohydrates such as glucose, sucrose, dextran, antioxidants such as ascorbic acid and glutathione, chelating agents, low molecular weight proteins, other stabilizers, etc. can be used as drugs.

[0288] The dosage and frequency of administration of the pharmaceutical composition of the present invention are determined by the type of active ingredient, as well as various related factors such as the disease to be treated, the administration route, the age, sex and weight of the patient, and the severity of the disease.

[0289] The total effective amount of the composition of the present invention may be administered to a patient in a single dose or in a fractionated treatment protocol in which multiple doses are administered over a long period of time. The pharmaceutical composition of the present invention may have a different content of active ingredients depending on the severity of the disease. Specifically, the total dose of the conjugate of the present invention is preferably about 0.0001 mg to 500 mg per kg of body weight per day. However, the dose of the conjugate is determined by taking into consideration various factors such as the age, body weight, health condition, sex, severity of the disease, diet, and excretion rate of the patient as well as the administration route and number of treatments of the pharmaceutical composition, and therefore, taking these into consideration, a person having ordinary knowledge in the art would be able to determine an appropriate effective dose according to a specific use of the composition of the present invention. The pharmaceutical composition of the present invention is not particularly limited in its dosage form, administration route, and administration method as long as it exhibits the effects of the present invention.

[0290] In addition, the pharmaceutical composition of the present invention may contain 0.01 to 99% (w / v) of the above-mentioned concomitant drug, i.e., the triple activity agent or its long-acting conjugate, and insulin or its long-acting conjugate (or each component of the above-mentioned concomitant drug).

[0291] One aspect of the present invention provides a combination formulation for weight loss in insulin-treated patients, comprising (i) insulin and (ii) isolated peptides having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0292] The components contained in the composition, together with the insulin and the isolated peptides having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor, are as described above.

[0293] Specifically, the composite preparation may be (a) one comprising insulin and a triple-active substance, (b) one comprising a long-acting conjugate of insulin in which insulin is bound to a biocompatible substance capable of extending its in vivo half-life, and a triple-active substance, (c) one comprising insulin and a long-acting conjugate of a triple-active substance in which insulin is bound to a biocompatible substance capable of extending its in vivo half-life, or (d) one comprising a long-acting conjugate of insulin and a long-acting conjugate of a triple-active substance.

[0294] Specifically, the composite preparation contains both insulin or a long-acting conjugate thereof and a triple-active form or a long-acting conjugate thereof, in which the molar ratio of insulin:triple-active form is 1:1 to 100:1, or the molar ratio of insulin:triple-active form is 1:1 to 1:100, or the molar ratio of insulin or a long-acting conjugate thereof:triple-active form or long-acting conjugate thereof is 1:1 to 100:1, or the molar ratio of insulin or a long-acting conjugate thereof:triple-active form or long-acting conjugate thereof is 1:1 to 1:100, but is not limited thereto.

[0295] One embodiment of the present invention provides a kit comprising (i) insulin and (ii) isolated peptides having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0296] The isolated peptides having activity against insulin, glucagon receptor, GLP-1 receptor and GIP receptor have been described above.

[0297] The kit may include instructions for administration of (i) insulin and (ii) isolated peptides having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0298] Specifically, the kit may comprise (a) insulin and a triple-active agent, (b) a long-acting conjugate of insulin in which insulin is conjugated with a biocompatible substance capable of extending its in vivo half-life, and the triple-active agent, (c) insulin and a long-acting conjugate of the triple-active agent in which insulin is conjugated with a biocompatible substance capable of extending its in vivo half-life, or (d) a long-acting conjugate of insulin and a long-acting conjugate of the triple-active agent.

[0299] Specifically, the kit may contain both insulin or a long-acting conjugate thereof, and a triple-active form or a long-acting conjugate thereof, and may include instructions for administering to an individual insulin:triple-active form in a molar ratio of 1:1 to 100:1, or a molar ratio of 1:1 to 1:100, or may include instructions for administering to an individual insulin or a long-acting conjugate thereof:triple-active form or a long-acting conjugate thereof in a molar ratio of 1:1 to 100:1, or a molar ratio of 1:1 to 1:100, but is not limited to these.

[0300] One aspect of the realisation of the present invention provides the use of a composition or a combined formulation comprising (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor in the manufacture of a medicament.

[0301] The composition or the combined preparation is as described above. The drug can be used for all of the above-mentioned purposes.

[0302] One embodiment of the present invention provides a method for preventing or treating an insulin-related disorder, comprising administering to an individual (i) insulin and (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0303] One embodiment of the present invention provides a method for reducing weight gain due to insulin administration comprising administering to an individual an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0304] Specifically, one embodiment of the present invention provides a method for reducing weight gain due to insulin administration, comprising administering to an individual (i) insulin and (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[0305] The individual may be an individual at risk of developing an insulin-related disease, or an individual who has developed an insulin-related disease, or an individual who requires insulin administration, or an individual who requires insulin administration and is in need of weight loss, but is not limited thereto.

[0306] The administering step may be carried out by (a) co-administering insulin and the triple activity form, (b) co-administering a long-acting conjugate of insulin and the triple activity form, (c) co-administering insulin and a long-acting conjugate of the triple activity form, or (d) co-administering a long-acting conjugate of insulin and a long-acting conjugate of the triple activity form.

[0307] "Combination" in this application should be understood to mean simultaneous, sequential or separate administration. If said administration is sequential or separate, the interval between administration of the second component must be such that the beneficial effect of said combination is not lost.

[0308] The substances may be administered simultaneously, sequentially or in reverse order, and may be administered simultaneously in any suitable effective amount combination, but are not limited to any particular method or sequence of administration.

[0309] Furthermore, the preventive or therapeutic method of the present invention involves administering to an individual a composition or a combined preparation containing any of the above (a) to (d), but is not limited thereto.

[0310] The composition or composite preparation of the present invention, which contains insulin or a long-acting conjugate thereof and a triple-active substance or a long-acting conjugate thereof, supplements the activity or function of insulin, significantly lowers blood sugar, and suppresses the side effects of insulin, such as weight gain, and is therefore highly effective in treating insulin-related diseases.

[0311] Furthermore, the composition or composite preparation can be formulated into a single-dose preparation suitable for administration to the patient's body by a conventional method in the pharmaceutical field, specifically into a preparation form useful for administration of protein pharmaceuticals, and administered orally or via a parenteral administration route, including dermal, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, intragastrointestinal, topical, sublingual, intravaginal or rectal routes, but is not limited to these.

[0312] The method of the present invention may include administering a pharmaceutical composition comprising the active ingredient in a pharma- ceutical effective amount. The appropriate total daily dose is determined by the attending physician within the scope of sound medical judgment and may be administered in one or several doses. However, for purposes of the present invention, the specific therapeutically effective amount for a particular patient will preferably vary depending on a variety of factors, including the type and extent of the response to be achieved, whether or not other formulations are used, the specific composition, the patient's age, weight, general health, sex, diet, time of administration, route of administration, excretion rate of the composition, duration of treatment, drugs administered with or simultaneously with the specific composition, and similar factors well known in the pharmaceutical arts.

[0313] Specifically, insulin or its long-acting conjugate and triple activity form or long-acting conjugate thereof may be administered to an individual in a molar ratio of insulin:triple activity form of 1:1 to 100:1, or a molar ratio of 1:1 to 1:100, or insulin or its long-acting conjugate:triple activity form or long-acting conjugate thereof may be administered to an individual in a molar ratio of 1:1 to 100:1, or a molar ratio of 1:1 to 1:100, but is not limited to these.

[0314] The present invention will be described in more detail below with reference to examples. However, these examples are merely illustrative of the present invention and are not intended to limit the present invention. EXAMPLES

[0315] Preparation of triple-active compounds and their long-acting conjugates (1) Preparation of triple-active mutants We have constructed a triple-active substance that has activity at the glucagon receptor, the GLP-1 receptor, and the GIP receptor. The sequence is shown in Table 1.

[0316] [Table 1] TIFF0007596268000003.tif161145 TIFF0007596268000004.tif166144 TIFF0007596268000005.tif171145 TIFF0007596268000006.tif171144 TIFF0007596268000007.tif182145 TIFF0007596268000008.tif187148 TIFF0007596268000009.tif229151

[0317] In the sequences of Table 1, the amino acid represented by X means the unnatural amino acid Aib (aminoisobutyric acid), and the underlined amino acids mean that the amino acids form a ring with each other. In addition, in the sequences of Table 1, CA means 4-imidazoacetyl, and Y means tyrosine.

[0318] (2) Preparation of a long-acting triple-active conjugate In order to PEGylate the cysteine ​​residues of the triple-active substance of Example 1 (SEQ ID NOs: 21, 22, 42, 43, 50, 77, and 96) with 10 kDa PEG having a maleimide group and an aldehyde group at each end, i.e., maleimide-PEG-aldehyde (10 kDa, NOF, Japan), the molar ratio of the triple-active substance to maleimide-PEG-aldehyde was set to 1:1-3, the protein concentration was set to 1-5 mg / ml, and the reaction was carried out at a low temperature for 0.5-3 hours. Here, the reaction was carried out in an environment where 20-60% isopropanol was added to 50 mM Tris buffer (pH 7.5). After the reaction was completed, the reaction solution was applied to SP Sepharose HP (GE Healthcare, USA) to purify the triple-active substance mono-PEGylated to cysteine.

[0319] Next, the purified monoPEGylated triple active substance and immunoglobulin Fc were reacted at a molar ratio of 1:1-5, a protein concentration of 10-50 mg / ml, and at 4-8°C for 12-18 hours. The reaction was carried out in an environment where 100 mM potassium phosphate buffer (pH 6.0) was added with 10-50 mM sodium cyanoborohydride as a reducing agent and 10-30% isopropanol. After the reaction was completed, the reaction solution was applied to a Butyl Sepharose FF purification column (GE Healthcare, USA) and a Source ISO purification column (GE Healthcare, USA) to purify a conjugate containing the triple active substance and immunoglobulin Fc.

[0320] After preparation, the purity was analyzed by reverse phase chromatography, size exclusion chromatography, and ion exchange chromatography and was found to be 95% or more.

[0321] Here, the conjugate in which the triple activity of SEQ ID NO:21 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO:21 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO:21" or "a long-acting conjugate of SEQ ID NO:21". These terms are used interchangeably in the present application.

[0322] Herein, the conjugate in which the triple activity of SEQ ID NO:22 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO:22 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO:22" or "a long-acting conjugate of SEQ ID NO:22". These terms are used interchangeably in the present application.

[0323] Herein, the conjugate in which the triple activity of SEQ ID NO: 42 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO: 42 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO: 42" or "a long-acting conjugate of SEQ ID NO: 42". These terms are used interchangeably in the present application.

[0324] Here, the conjugate in which the triple activity of SEQ ID NO: 43 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO: 43 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO: 43" or "a long-acting conjugate of SEQ ID NO: 43". These terms are used interchangeably in the present application.

[0325] Here, the conjugate in which the triple activity of SEQ ID NO:50 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO:50 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO:50" or "a long-acting conjugate of SEQ ID NO:50". These terms are used interchangeably in the present application.

[0326] Herein, the conjugate in which the triple activity of SEQ ID NO: 77 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO: 77 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO: 77" or "a long-acting conjugate of SEQ ID NO: 77". These terms are used interchangeably in the present application.

[0327] Herein, the conjugate in which the triple activity of SEQ ID NO: 96 and immunoglobulin Fc are linked via PEG is named "a conjugate comprising SEQ ID NO: 96 and immunoglobulin Fc", "a long-acting conjugate of SEQ ID NO: 96" or "a long-acting conjugate of SEQ ID NO: 96". These terms are used interchangeably in the present application. EXAMPLES

[0328] Preparation of long-acting conjugates of native insulin To PEGylate the N-terminus of the B chain of natural human insulin (Biocon, India) with 3.4K propion-ALD(2) PEG (3.4 kDa PEG with one propionaldehyde group at each end, NOF, USA), the molar ratio of natural insulin:PEG was set to 1:4, the concentration of natural insulin was set to 5 mg / ml, and the reaction was carried out at 4°C for about 2 hours. The reaction was carried out in a mixed solvent of 50 mM sodium citrate buffer (pH 5.0) and 45% isopropanol, with the addition of a reducing agent of sodium cyanoborohydride (NaCNBH3) at a concentration of 3 mM. The reaction solution was purified on a SP-HP (GE Healthcare) column using a buffer containing sodium citrate (pH 3.0), 45% EtOH, and a concentration gradient of KCl.

[0329] Next, in order to bind the PEG to which the native insulin was bound to the N-terminus of the immunoglobulin Fc fragment, the purified mono-PEGylated insulin and the immunoglobulin Fc fragment were reacted at a molar ratio of 1:1.2, a total protein concentration of 20 mg / ml, and at 25° C. for 15 hours. The reaction solution was 100 mM HEPES buffer (pH 8.2) and sodium chloride, to which 20 mM sodium cyanoborohydride was added as a reducing agent.

[0330] After the reaction was completed, the reaction solution was applied to a Q-HP (GE, USA) column using a concentration gradient of Tris-HCl (pH 7.5) buffer and NaCl, and then applied to a Source 15ISO (GE, USA) using a concentration gradient of ammonium sulfate and Tris-HCl (pH 7.5) to purify the native insulin-3.4K PEG-immunoglobulin Fc conjugate.

[0331] Experimental Example 1: Measurement of in vitro activity of triple-active complex and its long-acting conjugate In order to measure the activity of the triple-active substance and its long-acting conjugate prepared in Example 1, a method for measuring cellular activity in vitro was performed using cell lines transformed with GLP-1 receptor, glucagon (GCG) receptor, and GIP receptor, respectively.

[0332] The above cell lines were transformed into CHO (chinese hamster ovary) cells to express human GLP-1 receptor, human GCG receptor, and human GIP receptor genes, respectively, and are suitable for measuring the activity of GLP-1, GCG, and GIP. Therefore, the activity of each part was measured using each transformed cell line.

[0333] To measure the GLP-1 activity of the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2, human GLP-1 was serially diluted, and the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2 were serially diluted. The culture medium was removed from the cultured CHO cells expressing human GLP-1 receptor, and 5 μl of each of the serially diluted substances was added to the cells, followed by adding 5 μl of a buffer containing a cAMP antibody, and then culturing at room temperature for 15 minutes. Next, 10 μl of a detection mix containing a cell lysis buffer was added to lyse the cells, and the reaction was allowed to proceed at room temperature for 90 minutes. The cell lysate after the reaction was applied to a LANCE cAMP kit (PerkinElmer, USA) to extract EC from the accumulated cAMP. 50 The values ​​were calculated and compared with each other. The relative potencies against human GLP-1 are shown in Tables 2 and 3.

[0334] To measure the GCG activity of the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2, human GCG was serially diluted, and the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2 were serially diluted. The culture medium was removed from the cultured CHO cells expressing human GCG receptor, and 5 μl of each of the serially diluted substances was added to the cells, followed by adding 5 μl of a buffer containing a cAMP antibody, and then culturing at room temperature for 15 minutes. Next, 10 μl of a detection mix containing a cell lysis buffer was added to lyse the cells, and the reaction was allowed to proceed at room temperature for 90 minutes. The cell lysate after the reaction was applied to a LANCE cAMP kit (PerkinElmer, USA) to extract EC from the accumulated cAMP. 50 The values ​​were calculated and compared with each other. The relative potencies against human GCG are shown in Tables 2 and 3.

[0335] To measure the GIP activity of the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2, human GIP was serially diluted, and the triple activity complex and its long-acting conjugate prepared in Examples 1 and 2 were serially diluted. The culture medium was removed from the cultured CHO cells expressing human GIP receptor, and 5 μl of each of the serially diluted substances was added to the cells, followed by adding 5 μl of a buffer containing a cAMP antibody, and then culturing at room temperature for 15 minutes. Next, 10 μl of a detection mix containing a cell lysis buffer was added to lyse the cells, and the reaction was allowed to proceed at room temperature for 90 minutes. The cell lysate after the reaction was applied to a LANCE cAMP kit (PerkinElmer, USA) to extract EC from the accumulated cAMP. 50 The values ​​were calculated and compared with each other. The relative potencies against human GIP are shown in Tables 2 and 3.

[0336] Relative potency of triple activity [Table 2] TIFF0007596268000011.tif197148 TIFF0007596268000012.tif208148

[0337] Relative potency of triple-active long-acting conjugates [Table 3]

[0338] Experimental Example 2: Confirmation of blood glucose control effect and body weight change (△Body weight) in type 2 diabetes model mice by combined administration of insulin long-acting conjugate and triple-active long-acting conjugate To measure the in vivo efficacy of administering a composition containing the long-acting conjugate of the triple activity form (SEQ ID NO: 42) prepared in Example 1 or the long-acting conjugate of natural insulin prepared in Example 2, or administering the long-acting conjugate of the triple activity form (SEQ ID NO: 42) and the long-acting conjugate of natural insulin in combination, db / db mice (Charles River, Japan), a type 2 diabetes model, were used. db / db mice (BKS.Cg-+Lepr db / + Lepr db / OlaHsd mice) were used in this experiment because they show diabetic symptoms when the leptin receptor is removed.

[0339] Blood glucose was measured using a blood glucose analyzer (OneTouch Ultra, LifeScan, Inc., USA) using 1-2 drops of blood obtained from the tail vein of 8-week-old db / db mice with a 26G syringe. Whether diabetes was induced was determined based on the measured blood glucose (range 350-600 mg / dl). Mice with diabetes induced were divided into 4 groups, G1, G2, G3, and G4, with 7 mice per group, according to blood glucose.

[0340] The above groups were divided into a control group (Vehicle), a group administered a long-acting conjugate of natural insulin (15.8 nmol / kg / Q2D), a group administered a long-acting conjugate of triple activity (1.4 nmol / kg / Q2D), and a group administered a long-acting conjugate of natural insulin (15.8 nmol / kg / Q2D) and a long-acting conjugate of triple activity (1.4 nmol / kg / Q2D) in combination. The above test substances were administered repeatedly for two weeks, and then glycated hemoglobin (HbA1c) was measured for each group. Glycohemoglobin is a form in which sugar is bound to hemoglobin normally present in red blood cells, and if blood glucose is maintained at a high level, the glycated hemoglobin value will also increase. In addition, the body weight change (△Body weight) of the test animals was calculated before drug administration and on the final day of the test.

[0341] As a result, it was confirmed that the glycohemoglobin level was decreased in the group administered the long-acting conjugate of natural insulin and the long-acting conjugate of the triple activity compound in combination (Figure 1). Specifically, in Figure 1, the change in glycohemoglobin level compared to the control group was -0.1 in the group administered the long-acting conjugate of insulin, -0.3 in the group administered the long-acting conjugate of triple activity compound, and -0.5 in the group administered the long-acting conjugate of insulin and the long-acting conjugate of triple activity compound in combination.

[0342] This is a marked improvement over the groups administered the long-acting conjugate of native insulin or the long-acting conjugate of the triple activity form, respectively.

[0343] △Body weight measurements showed that the group administered the long-acting conjugate of natural insulin and the long-acting conjugate of triple activity compound in combination not only showed improved weight gain compared to the group administered the long-acting conjugate of natural insulin alone, but also showed a significant weight loss effect compared to the control group (Figure 2). Specifically, as shown in Figure 2, the control group was +15.8%, the group administered the long-acting conjugate of insulin was +23.1%, the group administered the long-acting conjugate of triple activity compound was -9.3%, and the group administered the long-acting conjugate of insulin and the long-acting conjugate of triple activity compound in combination was -3.8%.

[0344] These results indicate that the combined administration of the long-acting insulin conjugate and the long-acting triple activity compound of the present invention exhibits superior blood glucose regulating effects compared to either compound administered alone, and also suggest that the combined administration of the long-acting insulin conjugate and the long-acting triple activity compound significantly reduces the side effect of weight gain caused by administration of insulin alone.

[0345] From the above description, a person skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical ideas or essential features. It should be understood that the above examples are merely illustrative and not limiting. The present invention should be interpreted as including all modifications and alterations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification. Yet another aspect of the present invention may be as follows. [1] (i) insulin, (ii) A pharmaceutical composition for preventing or treating an insulin-related disease, comprising an isolated peptide having activity against a glucagon receptor, a glucagon-like peptide-1 (GLP-1) receptor, and a glucose-dependent insulinotropic polypeptide (GIP) receptor. [2] The composition according to [1], wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its half-life in vivo is attached. [3] The composition described in [1], wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached. [4] The insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound, The composition described in [1] above, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached. [5] The composition described in [1] above, wherein the composition is administered to an individual requiring insulin administration. [6] The composition according to [1] above, wherein the insulin-related disease is selected from the group consisting of insulin resistance disease, diabetes, hyperglycemia and obesity. [7] The composition according to any one of [1] to [6] above, which has both a blood glucose lowering effect and an effect of suppressing weight gain that occurs when insulin is administered alone. [8] The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The composition according to any one of [1] to [6] above, comprising insulin or a conjugate thereof:an isolated peptide or a conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, in a molar ratio of 1:1 to 100:1. [9] The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The composition according to any one of [1] to [6] above, comprising insulin or a conjugate thereof:an isolated peptide or a conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor and a GIP receptor in a molar ratio of 1:1 to 1:100.

[10] The composition according to any one of [1] to [6], wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is an analogue of native glucagon having an alteration selected from the group consisting of substitution, addition, deletion, modification and combinations thereof of at least one amino acid in the native glucagon sequence.

[11] The composition according to

[10] above, wherein the added amino acid sequence is derived from the amino acid sequence of natural GLP-1, natural GIP, or natural exendin-4.

[12] The composition according to [1], wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is a peptide comprising an amino acid sequence represented by the following general formula 1: Xaa1-Xaa2-Xaa3-Gly-Thr-Phe-Xaa7-Ser-Asp-Xaa10-Ser-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-X aa18-Xaa19-Xaa20-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Xaa27-Xaa28-Xaa29-Xaa30-R1 (general formula 1, sequence number 103) In the general formula 1, Xaa1 is histidine (His, H), 4-imidazoacetyl (CA) or tyrosine (Tyr, Y); Xaa2 is glycine (Gly, G), α-methylglutamic acid, or Aib (aminoisobutyric acid); Xaa3 is glutamic acid (Glu, E) or glutamine (Gln, Q); Xaa7 is threonine (Thr, T) or isoleucine (Ile, I); Xaa10 is leucine (Leu, L), tyrosine (Tyr, Y), lysine (Lys, K), cysteine ​​(Cys, C) or valine (Val, V); Xaa12 is lysine (Lys, K), serine (Ser, S) or isoleucine (Ile, I); Xaa13 is glutamine (Gln, Q), tyrosine (Tyr, Y), alanine (Ala, A) or cysteine ​​(Cys, C); Xaa14 is leucine (Leu, L), methionine (Met, M) or tyrosine (Tyr, Y); Xaa15 is cysteine ​​(Cys, C), aspartic acid (Asp, D), glutamic acid (Glu, E) or leucine (Leu, L); Xaa16 is glycine (Gly, G), glutamic acid (Glu, E) or serine (Ser, S); Xaa17 is glutamine (Gln, Q), arginine (Arg, R), isoleucine (Ile, I), glutamic acid (Glu, E), cysteine ​​(Cys, C) or lysine (Lys, K); Xaa18 is alanine (Ala, A), glutamine (Gln, Q), arginine (Arg, R) or histidine (His, H); Xaa19 is alanine (Ala, A), glutamine (Gln, Q), cysteine ​​(Cys, C) or valine (Val, V); Xaa20 is lysine (Lys, K), glutamine (Gln, Q) or arginine (Arg, R); Xaa21 is glutamic acid (Glu, E), glutamine (Gln, Q), leucine (Leu, L), cysteine ​​(Cys, C) or aspartic acid (Asp, D); Xaa23 is isoleucine (Ile, I) or valine (Val, V); Xaa24 is alanine (Ala, A), glutamine (Gln, Q), cysteine ​​(Cys, C), asparagine (Asn, N), aspartic acid (Asp, D) or glutamic acid (Glu, E); Xaa27 is valine (Val, V), leucine (Leu, L), lysine (Lys, K) or methionine (Met, M); Xaa28 is cysteine ​​(Cys, C), lysine (Lys, K), alanine (Ala, A), asparagine (Asn, N) or aspartic acid (Asp, D); Xaa29 is cysteine ​​(Cys, C), glycine (Gly, G), glutamine (Gln, Q), threonine (Thr, T), glutamic acid (Glu, E) or histidine (His, H); Xaa30 is cysteine ​​(Cys, C), glycine (Gly, G), lysine (Lys, K), histidine (His, H), or is absent; R1 is cysteine ​​(Cys,C), GKKNDWKHNIT (SEQ ID NO:106), m-SSGAPPPS-n (SEQ ID NO:107), or m-SSGQPPPS-n (SEQ ID NO:108), or is absent; Where: m is Cys, Pro or Gly-Pro; n is Cys, Gly, Ser, His-Gly, or is absent.

[13] The composition according to

[12] above, wherein Xaa14 is leucine or methionine, and Xaa15 is cysteine, aspartic acid, or leucine.

[14] In the above general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib; Xaa7 is threonine, Xaa10 is tyrosine, cysteine ​​or valine; Xaa12 is lysine or isoleucine; Xaa13 is tyrosine, alanine, glutamine or cysteine; Xaa14 is leucine, cysteine ​​or methionine; Xaa15 is cysteine, leucine, glutamic acid or aspartic acid; Xaa17 is glutamine, arginine, isoleucine, cysteine, glutamic acid, or lysine; Xaa18 is alanine, glutamine, arginine or histidine; Xaa19 is alanine, glutamine, valine or cysteine; Xaa20 is lysine, arginine or glutamine; Xaa21 is glutamic acid, glutamine, leucine, cysteine, or aspartic acid; Xaa23 is isoleucine or valine; Xaa24 is cysteine, alanine, glutamine, asparagine, glutamic acid, or aspartic acid; The composition according to claim 12, wherein Xaa27 is leucine or lysine.

[15] The composition according to

[12] , wherein the peptide is a peptide comprising an amino acid sequence represented by the following general formula 2: Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Xaa10-Ser-Lys-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa2 1-Phe-Xaa23-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 2, SEQ ID NO: 104) In the general formula 2, Xaa1 is 4-imidazoacetyl, histidine or tyrosine; Xaa2 is glycine, α-methylglutamic acid, or Aib; Xaa10 is tyrosine or cysteine; Xaa13 is alanine, glutamine, tyrosine, or cysteine; Xaa14 is leucine, methionine or tyrosine; Xaa15 is aspartic acid, glutamic acid, or leucine; Xaa16 is glycine, glutamic acid, or serine; Xaa17 is glutamine, arginine, isoleucine, glutamic acid, cysteine, or lysine; Xaa18 is alanine, glutamine, arginine or histidine; Xaa19 is alanine, glutamine, cysteine, or valine; Xaa20 is lysine, glutamine or arginine; Xaa21 is cysteine, glutamic acid, glutamine, leucine, or aspartic acid; Xaa23 is isoleucine or valine; Xaa24 is cysteine, alanine, glutamine, asparagine, or glutamic acid; Xaa28 is lysine, cysteine, asparagine, or aspartic acid; Xaa29 is glycine, glutamine, cysteine ​​or histidine; Xaa30 is cysteine, glycine, lysine or histidine; Xaa31 is proline or cysteine; Xaa40 is a cysteine ​​or is absent.

[16] In the above general formula 1, Xaa2 is glycine, α-methylglutamic acid, or Aib; Xaa7 is threonine, Xaa10 is tyrosine, cysteine ​​or valine; Xaa12 is lysine or isoleucine; Xaa13 is tyrosine, alanine or cysteine; Xaa14 is leucine or methionine; Xaa15 is cysteine ​​or aspartic acid; Xaa17 is glutamine, arginine, isoleucine, cysteine, or lysine; Xaa18 is alanine, arginine or histidine; Xaa19 is alanine, glutamine or cysteine; Xaa20 is lysine or glutamine; Xaa21 is glutamic acid, cysteine, or aspartic acid; Xaa23 is valine, Xaa24 is alanine, glutamine, cysteine, asparagine, or aspartic acid; The composition according to claim 12, wherein Xaa27 is leucine or lysine.

[17] In the above general formula 2, Xaa13 is alanine, tyrosine or cysteine; Xaa15 is aspartic acid or glutamic acid; Xaa17 is glutamine, arginine, cysteine ​​or lysine; Xaa18 is alanine, arginine or histidine; Xaa21 is cysteine, glutamic acid, glutamine or aspartic acid; Xaa23 is isoleucine or valine; Xaa24 is cysteine, glutamine or asparagine; Xaa28 is cysteine, asparagine or aspartic acid; Xaa29 is glutamine, cysteine ​​or histidine; The composition according to claim 15, wherein Xaa30 is cysteine, lysine or histidine.

[18] In the above general formula 1, Xaa2 is α-methylglutamic acid or Aib; Xaa7 is threonine, Xaa10 is tyrosine or cysteine; Xaa12 is lysine or isoleucine; Xaa13 is tyrosine, alanine or cysteine; Xaa14 is leucine or methionine; Xaa15 is cysteine ​​or aspartic acid; Xaa16 is glutamic acid, Xaa17 is arginine, isoleucine, cysteine ​​or lysine; Xaa18 is alanine, arginine or histidine; Xaa19 is alanine, glutamine or cysteine; Xaa20 is lysine or glutamine; Xaa21 is glutamic acid or aspartic acid; Xaa23 is valine, Xaa24 is glutamine, asparagine, or aspartic acid; Xaa27 is leucine, The composition according to claim 12, wherein Xaa28 is cysteine, alanine, asparagine or aspartic acid.

[19] In the above general formula 1, Xaa1 is histidine or 4-imidazoacetyl; Xaa2 is α-methylglutamic acid or Aib; Xaa3 is glutamine, Xaa7 is threonine, Xaa10 is tyrosine, Xaa12 is isoleucine, Xaa13 is alanine or cysteine; Xaa14 is methionine, Xaa15 is aspartic acid, Xaa16 is glutamic acid, Xaa17 is isoleucine or lysine; Xaa18 is alanine or histidine; Xaa19 is glutamine or cysteine; Xaa20 is lysine, Xaa21 is aspartic acid, Xaa23 is valine, Xaa24 is asparagine, Xaa27 is leucine, Xaa28 is alanine or asparagine; Xaa29 is glutamine or threonine; The composition according to claim 12, wherein Xaa30 is cysteine ​​or lysine, or is absent.

[20] The composition according to

[11] , wherein the peptide is a peptide comprising an amino acid sequence represented by the following general formula 3: Xaa1-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Xaa13-Leu-Asp-Glu-Xaa17-Xaa18-Xaa19-Lys-Xaa21-Ph e-Val-Xaa24-Trp-Leu-Leu-Xaa28-Xaa29-Xaa30-Xaa31-Ser-Ser-Gly-Gln-Pro-Pro-Pro-Ser-Xaa40 (general formula 3, SEQ ID NO: 105) In the general formula 3, Xaa1 is histidine or tyrosine; Xaa2 is α-methylglutamic acid or Aib; Xaa13 is alanine, tyrosine or cysteine; Xaa17 is arginine, cysteine ​​or lysine; Xaa18 is alanine or arginine; Xaa19 is alanine or cysteine; Xaa21 is glutamic acid or aspartic acid; Xaa24 is glutamine or asparagine; Xaa28 is cysteine ​​or aspartic acid; Xaa29 is cysteine, histidine or glutamine; Xaa30 is cysteine ​​or histidine; Xaa31 is proline or cysteine; Xaa40 is a cysteine ​​or is absent.

[21] The composition described in

[12] , wherein R1 is cysteine, GKKNDWKHNIT (sequence number 106), CSSGQPPPS (sequence number 109), GPSSGAPPPS (sequence number 110), GPSSGAPPPSC (sequence number 111), PSSGAPPPS (sequence number 112), PSSGAPPPSG (sequence number 113), PSSGAPPPSHG (sequence number 114), PSSGAPPPSS (sequence number 115), PSSGQPPPS (sequence number 116) or PSSGQPPPSC (sequence number 117), or is absent.

[22] The composition described in

[12] , wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor, and the GIP receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 102.

[23] The composition described in

[12] , wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises the amino acid sequence of SEQ ID NO: 42.

[24] The composition according to any one of

[12] to

[21] above, wherein in the general formula, the 16th amino acid and the 20th amino acid from the N-terminus form a ring together.

[25] The composition according to any one of

[12] to

[21] , wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor, and the GIP receptor is amidated at its C-terminus.

[26] The composition according to [1], wherein the insulin is a natural insulin or an insulin analogue in which at least one amino acid of natural insulin has been mutated by a mutation selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof.

[27] The composition of

[26] , wherein the insulin analog is an insulin analog mutated by substituting at least one amino acid selected from the group consisting of the 1st, 2nd, 3rd, 5th, 8th, 10th, 12th, 16th, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, and 30th amino acids of the B chain and the 1st, 2nd, 5th, 8th, 10th, 12th, 14th, 16th, 17th, 18th, 19th, and 21st amino acids of the A chain of native insulin with another amino acid, deleting it, or a combination thereof.

[28] The composition described in

[226] , wherein the insulin analog comprises an A chain of sequence number 119, represented by the following general formula 4, and a B chain of sequence number 120, represented by the following general formula 5. [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119) In the general formula 4, Xaa1 is alanine, glycine, glutamine, histidine, glutamic acid, or asparagine; Xaa2 is alanine or isoleucine; Xaa5 is alanine, glutamic acid, glutamine, histidine or asparagine; Xaa12 is alanine, serine, glutamine, glutamic acid, histidine, or asparagine; Xaa14 is alanine, tyrosine, glutamic acid, histidine, lysine, aspartic acid, or asparagine; Xaa16 is alanine, leucine, tyrosine, histidine, glutamic acid, or asparagine; Xaa19 is alanine, tyrosine, serine, glutamic acid, histidine, threonine, or asparagine; Xaa21 is asparagine, glycine, histidine, or alanine. [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu-Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120) In the general formula 5, Xaa8 is alanine or glycine; Xaa16 is tyrosine, glutamic acid, serine, threonine, aspartic acid, or is absent; Xaa23 is glycine or alanine; Xaa24 is alanine or phenylalanine; Xaa25 is alanine, phenylalanine, aspartic acid, glutamic acid, or is absent; Xaa27 is threonine or absent, Xaa28 is proline, glutamic acid, aspartic acid, or absent (except in peptides comprising chain A of SEQ ID NO:121 and chain B of SEQ ID NO:122).

[29] The composition of

[26] above, wherein the insulin analogue has one amino acid selected from the group consisting of the 8th, 23rd, 24th, and 25th amino acids of the B chain and the 1st, 2nd, and 19th amino acids of the A chain of natural insulin substituted with alanine, or the 14th amino acid of the A chain substituted with glutamic acid or asparagine.

[30] The composition described in

[29] , wherein the insulin analog comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 126, 128, 130, 132, 134, 136, 138 and 140.

[31] The composition according to

[26] , wherein the insulin analogue is an insulin analogue mutated by substituting the 16th amino acid of the B chain of natural insulin with glutamic acid, deleting the 25th amino acid, substituting the 14th amino acid of the A chain of natural insulin with glutamic acid or alanine, or a combination thereof.

[32] The composition described in

[31] , wherein the insulin analog comprises the amino acid sequence of SEQ ID NO: 142 or 144.

[33] The composition of

[26] above, wherein the insulin analogue is an insulin analogue mutated by substituting the 16th amino acid of the B chain of natural insulin with glutamic acid, serine, threonine or aspartic acid, the 25th amino acid of the B chain of natural insulin with aspartic acid or glutamic acid, the 14th amino acid of the A chain of natural insulin with histidine, lysine, alanine or aspartic acid, the 19th amino acid of the A chain of natural insulin with glutamic acid, serine or threonine, or a combination thereof.

[34] The composition described in

[33] , wherein the insulin analog comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168 and 170.

[35] The composition described in

[28] , wherein the insulin analogue is in the form of a double chain consisting of an A chain of sequence number 119 represented by general formula 4 and a B chain of sequence number 120 represented by general formula 5.

[36] The composition described in

[35] , wherein the A chain and the B chain are linked by a disulfide bond.

[37] The composition according to any one of [2] to [4] above, wherein the conjugate is represented by the following chemical formula 1: [Chemical formula 1] X-La-F Where: X is an isolated peptide having activity against the insulin or glucagon receptor, the GLP-1 receptor and the GIP receptor; L is a linker, a is 0 or a natural number, but if a is 2 or more, each L is independent of the others. F is a substance that can extend the in vivo half-life of X, The "-" represents a covalent or non-covalent bond.

[38] The composition according to

[37] , wherein F is selected from the group consisting of high molecular weight polymers, fatty acids, cholesterol, albumin and fragments thereof, albumin binding substances, polymers of repeating units of specific amino acid sequences, antibodies, antibody fragments, FcRn binding substances, in vivo connective tissue, nucleotides, fibronectin, transferrin, saccharides, heparin, and elastin.

[39] The composition described in

[38] , wherein the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

[40] The composition described in

[37] , wherein F is an immunoglobulin Fc region.

[41] The composition described in

[40] , wherein F is an IgG Fc region.

[42] The composition described in

[41] , wherein the immunoglobulin Fc region is non-glycosylated.

[43] The immunoglobulin Fc region comprises: (a) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, (b) a CH1 domain and a CH2 domain, (c) a CH1 domain and a CH3 domain, (d) a CH2 domain and a CH3 domain, (e) a combination of at least one of a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain with an immunoglobulin hinge region or a portion of a hinge region; and (f) the composition described in

[40] , which is selected from the group consisting of a dimer of each domain of a heavy chain constant region and a light chain constant region.

[44] The composition described in

[40] , wherein the immunoglobulin Fc region has a disulfide bond-forming site removed, some amino acids at the N-terminus of a native Fc region have been deleted, a methionine residue has been added to the N-terminus of a native Fc region, a complement binding site has been removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site has been removed.

[45] The composition described in

[40] , wherein the immunoglobulin Fc region is an immunoglobulin Fc fragment derived from IgG, IgA, IgD, IgE or IgM.

[46] The composition described in

[40] , wherein the immunoglobulin Fc region is a hybrid of domains having different origins derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.

[47] The composition according to

[37] , wherein L is selected from the group consisting of peptides, fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.

[48] ​​The composition described in

[47] , wherein the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

[49] The composition according to

[37] , wherein L is polyethylene glycol.

[50] (i) insulin, (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor, for use in the prevention or treatment of an insulin-related disease.

[51] (i) insulin, (ii) an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor, for reducing weight gain due to insulin administration.

[52] The composition according to

[51] , wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its half-life in vivo is attached.

[53] The composition described in

[51] , wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[54] The insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound. The composition described in

[51] above, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[55] (i) insulin, (ii) A combination formulation for weight loss in insulin-treated patients, comprising an isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor.

[56] The combined preparation according to

[55] , wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound.

[57] The combined preparation according to

[55] , wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

[58] The insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound. The combined preparation according to

[55] above, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound.

[59] The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The combined preparation according to any one of

[55] to

[58] above, comprising insulin:separated peptides active against a glucagon receptor, a GLP-1 receptor, and a GIP receptor in a molar ratio of 1:1 to 100:1.

[60] The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The combined preparation according to any one of

[55] to

[58] above, comprising insulin or a conjugate thereof:an isolated peptide or a conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor in a molar ratio of 1:1 to 1:100.

Claims

1. (i) insulin, (ii) A pharmaceutical composition for preventing or treating an insulin-related disease, comprising an isolated peptide having activity against a glucagon receptor, a glucagon-like peptide-1 (GLP-1) receptor, and a glucose-dependent insulinotropic polypeptide (GIP) receptor, The insulin is a natural insulin or an insulin analogue comprising an A-chain of SEQ ID NO: 119 and a B-chain of SEQ ID NO: 120 and having the general formula 4, the insulin-related disorder is selected from the group consisting of insulin resistance, diabetes, hyperglycemia and obesity; The isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence selected from SEQ ID NOs: 21, 22, 42, 43, 76, 96 and 97. [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119) [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu -Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120) ((1) In general formula 4, Xaa1 is alanine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (2) In general formula 4, Xaa1 is glycine, Xaa2 is alanine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (3) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is alanine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (4) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is alanine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (5) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is alanine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (6) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is alanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (7) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is alanine, Xaa27 is threonine, and Xaa28 is proline; (8) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (9) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is asparagine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (10) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (11) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (12) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is histidine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (13) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is lysine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (14) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is glutamic acid, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (15) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is serine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (16) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is threonine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (17) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (18) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is serine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (19) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is threonine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (20) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (21) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is aspartic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (22) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is aspartic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (23) In the general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in the general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is aspartic acid, Xaa27 is threonine, and Xaa28 is proline; or (24) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine; and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is glutamic acid, Xaa27 is threonine, and Xaa28 is proline.

2. The composition of claim 1 , wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

3. The composition of claim 1, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

4. the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound; The composition of claim 1, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

5. The composition of claim 1 , wherein the composition is administered to an individual in need of insulin administration.

6. The composition according to any one of claims 1 to 5, which has both a blood glucose lowering effect and an effect of suppressing weight gain that occurs when insulin is administered alone.

7. The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The composition according to any one of claims 1 to 5, comprising insulin or a long-acting conjugate thereof:an isolated peptide having activity against a glucagon receptor, a GLP-1 receptor and a GIP receptor or a long-acting conjugate thereof in a molar ratio of 1:1 to 100:

1.

8. The composition comprises insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The composition according to any one of claims 1 to 5, comprising insulin or a long-acting conjugate thereof:an isolated peptide having activity against a glucagon receptor, a GLP-1 receptor and a GIP receptor or a long-acting conjugate thereof in a molar ratio of 1:1 to 1:

100.

9. 2. The composition of claim 1, wherein the isolated peptide having activity at the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises the amino acid sequence of SEQ ID NO:

42.

10. The composition of claim 1 , wherein in the isolated peptide, the 16th and 20th amino acids from the N-terminus form a ring together.

11. The composition of claim 1, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is amidated at its C-terminus.

12. 2. The composition of claim 1, wherein the insulin analog comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 126, 128, 130, 132, 134, 136, 138 and 140.

13. The composition of claim 1 , wherein the insulin analog comprises the amino acid sequence of SEQ ID NO: 142 or 144.

14. 2. The composition of claim 1, wherein the insulin analog comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168 and 170.

15. The composition of claim 1, wherein the insulin analogue is in the form of a double chain consisting of an A chain of SEQ ID NO: 119 represented by the general formula 4 and a B chain of SEQ ID NO: 120 represented by the general formula 5.

16. The composition of claim 15, wherein the A and B chains are linked by a disulfide bond.

17. The composition according to any one of claims 2 to 4, wherein the conjugate is represented by the following chemical formula 1: [Chemical formula 1] X-La-F Where: X is an isolated peptide having activity against the insulin or glucagon receptor, the GLP-1 receptor and the GIP receptor; The isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence selected from SEQ ID NOs: 21, 22, 42, 43, 76, 96 and 97; L is a linker, a is 0 or a natural number, but if a is 2 or more, each L is independent of the others; F is a substance capable of extending the in vivo half-life of X, The "-" represents a covalent or non-covalent bond.

18. The composition of claim 17, wherein F is selected from the group consisting of high molecular weight polymers, fatty acids, cholesterol, albumin and fragments thereof, polymers of repeating units of specific amino acid sequences, antibodies, antibody fragments, immunoglobulin Fc regions, nucleotides, fibronectin, transferrin, saccharides, heparin, and elastin.

19. The composition according to claim 18, wherein the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

20. The composition of claim 18, wherein F is an IgG Fc region.

21. The composition of claim 20 , wherein the immunoglobulin Fc region is non-glycosylated.

22. The immunoglobulin Fc region is (a) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain; (b) a CH1 domain and a CH2 domain, (c) a CH1 domain and a CH3 domain, (d) a CH2 domain and a CH3 domain; (e) a combination of at least one of a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain with an immunoglobulin hinge region or a portion of a hinge region; and (f) a dimer of each domain of a heavy chain constant region and a light chain constant region. The composition of claim 18,

23. The composition of claim 18, wherein the immunoglobulin Fc region has a disulfide bond-forming site removed, some amino acids at the N-terminus of a native Fc region have been deleted, a methionine residue has been added to the N-terminus of a native Fc region, a complement binding site has been removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site has been removed.

24. 19. The composition of claim 18, wherein the immunoglobulin Fc region is an immunoglobulin Fc fragment derived from IgG, IgA, IgD, IgE, or IgM.

25. 20. The composition of claim 18, wherein the immunoglobulin Fc region is a hybrid of domains of different origin derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.

26. 18. The composition of claim 17, wherein L is selected from the group consisting of peptides, fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.

27. The composition of claim 26, wherein the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.

28. 27. The composition of claim 26, wherein L is polyethylene glycol.

29. (i) insulin, (ii) an isolated peptide having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, the insulin-related disorder is selected from the group consisting of insulin resistance, diabetes, hyperglycemia and obesity; The isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence selected from SEQ ID NOs: 21, 22, 42, 43, 76, 96 and 97, The insulin is a natural insulin or an insulin analogue comprising an A chain of SEQ ID NO: 119, represented by general formula 4, and a B chain of SEQ ID NO: 120, represented by general formula 5. [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119) [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu -Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120) ((1) In general formula 4, Xaa1 is alanine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (2) In general formula 4, Xaa1 is glycine, Xaa2 is alanine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (3) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is alanine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (4) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is alanine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (5) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is alanine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (6) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is alanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (7) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is alanine, Xaa27 is threonine, and Xaa28 is proline; (8) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (9) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is asparagine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (10) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (11) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (12) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is histidine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (13) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is lysine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (14) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is glutamic acid, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (15) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is serine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (16) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is threonine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (17) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (18) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is serine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (19) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is threonine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (20) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (21) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is aspartic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (22) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is aspartic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (23) In the general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in the general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is aspartic acid, Xaa27 is threonine, and Xaa28 is proline; or (24) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine; and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is glutamic acid, Xaa27 is threonine, and Xaa28 is proline.

30. (i) insulin, (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor, and the GIP receptor, The isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence selected from SEQ ID NOs: 21, 22, 42, 43, 76, 96 and 97, The composition, wherein the insulin is a natural insulin or an insulin analogue comprising an A chain of SEQ ID NO: 119, represented by general formula 4, and a B chain of SEQ ID NO: 120, represented by general formula 5. [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119) [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu -Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120) ((1) In general formula 4, Xaa1 is alanine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (2) In general formula 4, Xaa1 is glycine, Xaa2 is alanine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (3) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is alanine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (4) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is alanine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (5) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is alanine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (6) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is alanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (7) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is alanine, Xaa27 is threonine, and Xaa28 is proline; (8) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (9) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is asparagine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (10) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (11) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (12) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is histidine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (13) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is lysine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (14) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is glutamic acid, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (15) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is serine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (16) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is threonine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (17) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (18) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is serine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (19) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is threonine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (20) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (21) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is aspartic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (22) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is aspartic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (23) In the general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in the general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is aspartic acid, Xaa27 is threonine, and Xaa28 is proline; or (24) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine; and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is glutamic acid, Xaa27 is threonine, and Xaa28 is proline.

31. The composition of claim 30, wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

32. The composition of claim 30, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

33. the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound; The composition of claim 30, wherein the isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

34. (i) insulin, (ii) an isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor, The isolated peptide having activity against the glucagon receptor, the GLP-1 receptor and the GIP receptor comprises an amino acid sequence selected from SEQ ID NOs: 21, 22, 42, 43, 76, 96 and 97, and the insulin is a natural insulin or an insulin analogue comprising an A chain of SEQ ID NO: 119, represented by general formula 4, and a B chain of SEQ ID NO: 120, represented by general formula 5. [General formula 4] Xaa1-Xaa2-Val-Glu-Xaa5-Cys-Cys-Thr-Ser-Ile-Cys-Xaa12-Leu-Xaa14-Gln-Xaa16-Glu-Asn-Xaa19-Cys-Xaa21 (SEQ ID NO: 119) [General formula 5] Phe-Val-Asn-Gln-His-Leu-Cys-Xaa8-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa16-Leu -Val-Cys-Gly-Glu-Arg-Xaa23-Xaa24-Xaa25-Tyr-Xaa27-Xaa28-Lys-Thr (SEQ ID NO: 120) ((1) In general formula 4, Xaa1 is alanine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (2) In general formula 4, Xaa1 is glycine, Xaa2 is alanine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (3) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is alanine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (4) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is alanine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (5) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is alanine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (6) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is alanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (7) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is alanine, Xaa27 is threonine, and Xaa28 is proline; (8) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (9) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is asparagine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (10) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is glutamic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (11) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is absent, Xaa27 is threonine, and Xaa28 is proline; (12) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is histidine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (13) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is lysine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (14) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is glutamic acid, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (15) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is serine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (16) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is threonine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (17) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is glutamic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (18) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is serine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (19) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is threonine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (20) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is alanine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (21) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is aspartic acid, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (22) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in general formula 5, Xaa8 is glycine, Xaa16 is aspartic acid, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is phenylalanine, Xaa27 is threonine, and Xaa28 is proline; (23) In the general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine, and in the general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is aspartic acid, Xaa27 is threonine, and Xaa28 is proline; or (24) In general formula 4, Xaa1 is glycine, Xaa2 is isoleucine, Xaa5 is glutamine, Xaa12 is serine, Xaa14 is tyrosine, Xaa16 is leucine, Xaa19 is tyrosine, and Xaa21 is asparagine; and in general formula 5, Xaa8 is glycine, Xaa16 is tyrosine, Xaa23 is glycine, Xaa24 is phenylalanine, Xaa25 is glutamic acid, Xaa27 is threonine, and Xaa28 is proline.

35. The combination preparation according to claim 34, wherein the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is attached.

36. The combined preparation according to claim 34, wherein the isolated peptide having activity against glucagon receptor, GLP-1 receptor and GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound.

37. the insulin is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound; The combined preparation according to claim 34, wherein the isolated peptide having activity against glucagon receptor, GLP-1 receptor and GIP receptor is in the form of a long-acting conjugate to which a biocompatible substance capable of extending its in vivo half-life is bound.

38. The combined preparation contains insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The combined preparation according to any one of claims 34 to 37, comprising insulin:separate peptides active against glucagon receptor, GLP-1 receptor and GIP receptor in a molar ratio of 1:1 to 100:

1.

39. The combined preparation contains insulin or a long-acting conjugate thereof, and an isolated peptide or a long-acting conjugate thereof having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, The combined preparation according to any one of claims 34 to 37, comprising insulin or a long-acting conjugate thereof:an isolated peptide having activity against a glucagon receptor, a GLP-1 receptor and a GIP receptor or a long-acting conjugate thereof in a molar ratio of 1:1 to 1:100.

Citation Information

Patent Citations

  • Triple activator activating glucagon, GLP-1 and GIP receptor

    EP3398961A1

  • Double glp1 / gip or three-way glp1 / gip / glucagon agonist

    JP2016503772A

  • Novel insulin analog and use thereof

    KR1020140106452A

  • Novel Insulin Analogs and use thereof

    KR1020170026284A

  • Altered polypeptides with increased half-life

    WO1996032478A1